KR20000020495A - Detection method of malaria - Google Patents
Detection method of malaria Download PDFInfo
- Publication number
- KR20000020495A KR20000020495A KR1019980039110A KR19980039110A KR20000020495A KR 20000020495 A KR20000020495 A KR 20000020495A KR 1019980039110 A KR1019980039110 A KR 1019980039110A KR 19980039110 A KR19980039110 A KR 19980039110A KR 20000020495 A KR20000020495 A KR 20000020495A
- Authority
- KR
- South Korea
- Prior art keywords
- gly
- malaria
- asn
- lys
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000004792 malaria Diseases 0.000 title claims abstract description 80
- 238000001514 detection method Methods 0.000 title claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 34
- 206010037660 Pyrexia Diseases 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract description 18
- 102000018697 Membrane Proteins Human genes 0.000 abstract description 18
- 241000223810 Plasmodium vivax Species 0.000 abstract description 16
- 102000004169 proteins and genes Human genes 0.000 abstract description 15
- 210000003936 merozoite Anatomy 0.000 abstract description 5
- 238000001962 electrophoresis Methods 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 15
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- NHLAEBFGWPXFGI-WHFBIAKZSA-N Ala-Gly-Asn Chemical compound C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N NHLAEBFGWPXFGI-WHFBIAKZSA-N 0.000 description 6
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 6
- QPTNELDXWKRIFX-YFKPBYRVSA-N Gly-Gly-Gln Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O QPTNELDXWKRIFX-YFKPBYRVSA-N 0.000 description 6
- 108010057081 Merozoite Surface Protein 1 Proteins 0.000 description 6
- 108700005078 Synthetic Genes Proteins 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 6
- 108010047495 alanylglycine Proteins 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- XQGIRPGAVLFKBJ-CIUDSAMLSA-N Ala-Asn-Lys Chemical compound N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O XQGIRPGAVLFKBJ-CIUDSAMLSA-N 0.000 description 4
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 4
- PSUXEQYPYZLNER-QXEWZRGKSA-N Arg-Val-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PSUXEQYPYZLNER-QXEWZRGKSA-N 0.000 description 4
- 241000272470 Circus Species 0.000 description 4
- 238000007400 DNA extraction Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- YJIUYQKQBBQYHZ-ACZMJKKPSA-N Gln-Ala-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YJIUYQKQBBQYHZ-ACZMJKKPSA-N 0.000 description 4
- UXJHNZODTMHWRD-WHFBIAKZSA-N Gly-Asn-Ala Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O UXJHNZODTMHWRD-WHFBIAKZSA-N 0.000 description 4
- KMSGYZQRXPUKGI-BYPYZUCNSA-N Gly-Gly-Asn Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(N)=O KMSGYZQRXPUKGI-BYPYZUCNSA-N 0.000 description 4
- ZFNLIDNJUWNIJL-WDCWCFNPSA-N Leu-Glu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZFNLIDNJUWNIJL-WDCWCFNPSA-N 0.000 description 4
- 108010079364 N-glycylalanine Proteins 0.000 description 4
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 4
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 4
- ZZDFLJFVSNQINX-HWHUXHBOSA-N Trp-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N)O ZZDFLJFVSNQINX-HWHUXHBOSA-N 0.000 description 4
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 108010092854 aspartyllysine Proteins 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 108010054155 lysyllysine Proteins 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 210000003046 sporozoite Anatomy 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- PABFFPWEJMEVEC-JGVFFNPUSA-N Gly-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O PABFFPWEJMEVEC-JGVFFNPUSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- RBEATVHTWHTHTJ-KKUMJFAQSA-N Lys-Leu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O RBEATVHTWHTHTJ-KKUMJFAQSA-N 0.000 description 3
- 102100032467 Transmembrane protease serine 13 Human genes 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 108010062796 arginyllysine Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 108010050848 glycylleucine Proteins 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AAQGRPOPTAUUBM-ZLUOBGJFSA-N Ala-Ala-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O AAQGRPOPTAUUBM-ZLUOBGJFSA-N 0.000 description 2
- WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 2
- YAXNATKKPOWVCP-ZLUOBGJFSA-N Ala-Asn-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O YAXNATKKPOWVCP-ZLUOBGJFSA-N 0.000 description 2
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 2
- VBRDBGCROKWTPV-XHNCKOQMSA-N Ala-Glu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N VBRDBGCROKWTPV-XHNCKOQMSA-N 0.000 description 2
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 2
- VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 2
- IETUUAHKCHOQHP-KZVJFYERSA-N Ala-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)N)[C@@H](C)O)C(O)=O IETUUAHKCHOQHP-KZVJFYERSA-N 0.000 description 2
- XSLGWYYNOSUMRM-ZKWXMUAHSA-N Ala-Val-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XSLGWYYNOSUMRM-ZKWXMUAHSA-N 0.000 description 2
- OTOXOKCIIQLMFH-KZVJFYERSA-N Arg-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N OTOXOKCIIQLMFH-KZVJFYERSA-N 0.000 description 2
- RKRSYHCNPFGMTA-CIUDSAMLSA-N Arg-Glu-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O RKRSYHCNPFGMTA-CIUDSAMLSA-N 0.000 description 2
- NVUIWHJLPSZZQC-CYDGBPFRSA-N Arg-Ile-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NVUIWHJLPSZZQC-CYDGBPFRSA-N 0.000 description 2
- CTAPSNCVKPOOSM-KKUMJFAQSA-N Arg-Tyr-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O CTAPSNCVKPOOSM-KKUMJFAQSA-N 0.000 description 2
- ISVACHFCVRKIDG-SRVKXCTJSA-N Arg-Val-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O ISVACHFCVRKIDG-SRVKXCTJSA-N 0.000 description 2
- HZPSDHRYYIORKR-WHFBIAKZSA-N Asn-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O HZPSDHRYYIORKR-WHFBIAKZSA-N 0.000 description 2
- NUHQMYUWLUSRJX-BIIVOSGPSA-N Asn-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N NUHQMYUWLUSRJX-BIIVOSGPSA-N 0.000 description 2
- QHBMKQWOIYJYMI-BYULHYEWSA-N Asn-Asn-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O QHBMKQWOIYJYMI-BYULHYEWSA-N 0.000 description 2
- GNKVBRYFXYWXAB-WDSKDSINSA-N Asn-Glu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O GNKVBRYFXYWXAB-WDSKDSINSA-N 0.000 description 2
- OLGCWMNDJTWQAG-GUBZILKMSA-N Asn-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(N)=O OLGCWMNDJTWQAG-GUBZILKMSA-N 0.000 description 2
- PTSDPWIHOYMRGR-UGYAYLCHSA-N Asn-Ile-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O PTSDPWIHOYMRGR-UGYAYLCHSA-N 0.000 description 2
- YRTOMUMWSTUQAX-FXQIFTODSA-N Asn-Pro-Asp Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O YRTOMUMWSTUQAX-FXQIFTODSA-N 0.000 description 2
- HPNDBHLITCHRSO-WHFBIAKZSA-N Asp-Ala-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(O)=O HPNDBHLITCHRSO-WHFBIAKZSA-N 0.000 description 2
- VPPXTHJNTYDNFJ-CIUDSAMLSA-N Asp-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N VPPXTHJNTYDNFJ-CIUDSAMLSA-N 0.000 description 2
- NJIKKGUVGUBICV-ZLUOBGJFSA-N Asp-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O NJIKKGUVGUBICV-ZLUOBGJFSA-N 0.000 description 2
- OERMIMJQPQUIPK-FXQIFTODSA-N Asp-Arg-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O OERMIMJQPQUIPK-FXQIFTODSA-N 0.000 description 2
- GHODABZPVZMWCE-FXQIFTODSA-N Asp-Glu-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O GHODABZPVZMWCE-FXQIFTODSA-N 0.000 description 2
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 2
- ORRJQLIATJDMQM-HJGDQZAQSA-N Asp-Leu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O ORRJQLIATJDMQM-HJGDQZAQSA-N 0.000 description 2
- MYLZFUMPZCPJCJ-NHCYSSNCSA-N Asp-Lys-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MYLZFUMPZCPJCJ-NHCYSSNCSA-N 0.000 description 2
- OQMGSMNZVHYDTQ-ZKWXMUAHSA-N Asp-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N OQMGSMNZVHYDTQ-ZKWXMUAHSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 101710117490 Circumsporozoite protein Proteins 0.000 description 2
- AEJSNWMRPXAKCW-WHFBIAKZSA-N Cys-Ala-Gly Chemical compound SC[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O AEJSNWMRPXAKCW-WHFBIAKZSA-N 0.000 description 2
- UXIYYUMGFNSGBK-XPUUQOCRSA-N Cys-Gly-Val Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O UXIYYUMGFNSGBK-XPUUQOCRSA-N 0.000 description 2
- 108010090461 DFG peptide Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- SOBBAYVQSNXYPQ-ACZMJKKPSA-N Gln-Asn-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O SOBBAYVQSNXYPQ-ACZMJKKPSA-N 0.000 description 2
- JKGHMESJHRTHIC-SIUGBPQLSA-N Gln-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N JKGHMESJHRTHIC-SIUGBPQLSA-N 0.000 description 2
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 2
- JVSBYEDSSRZQGV-GUBZILKMSA-N Glu-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O JVSBYEDSSRZQGV-GUBZILKMSA-N 0.000 description 2
- AIGROOHQXCACHL-WDSKDSINSA-N Glu-Gly-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O AIGROOHQXCACHL-WDSKDSINSA-N 0.000 description 2
- UUTGYDAKPISJAO-JYJNAYRXSA-N Glu-Tyr-Leu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 UUTGYDAKPISJAO-JYJNAYRXSA-N 0.000 description 2
- BRFJMRSRMOMIMU-WHFBIAKZSA-N Gly-Ala-Asn Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O BRFJMRSRMOMIMU-WHFBIAKZSA-N 0.000 description 2
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 2
- GGEJHJIXRBTJPD-BYPYZUCNSA-N Gly-Asn-Gly Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GGEJHJIXRBTJPD-BYPYZUCNSA-N 0.000 description 2
- BULIVUZUDBHKKZ-WDSKDSINSA-N Gly-Gln-Asn Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BULIVUZUDBHKKZ-WDSKDSINSA-N 0.000 description 2
- FCKPEGOCSVZPNC-WHOFXGATSA-N Gly-Ile-Phe Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FCKPEGOCSVZPNC-WHOFXGATSA-N 0.000 description 2
- VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 2
- DBUNZBWUWCIELX-JHEQGTHGSA-N Gly-Thr-Glu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O DBUNZBWUWCIELX-JHEQGTHGSA-N 0.000 description 2
- GJHWILMUOANXTG-WPRPVWTQSA-N Gly-Val-Arg Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GJHWILMUOANXTG-WPRPVWTQSA-N 0.000 description 2
- MDBYBTWRMOAJAY-NHCYSSNCSA-N His-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N MDBYBTWRMOAJAY-NHCYSSNCSA-N 0.000 description 2
- XLCZWMJPVGRWHJ-KQXIARHKSA-N Ile-Glu-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N XLCZWMJPVGRWHJ-KQXIARHKSA-N 0.000 description 2
- OTSVBELRDMSPKY-PCBIJLKTSA-N Ile-Phe-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N OTSVBELRDMSPKY-PCBIJLKTSA-N 0.000 description 2
- OWSWUWDMSNXTNE-GMOBBJLQSA-N Ile-Pro-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N OWSWUWDMSNXTNE-GMOBBJLQSA-N 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- VCSBGUACOYUIGD-CIUDSAMLSA-N Leu-Asn-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VCSBGUACOYUIGD-CIUDSAMLSA-N 0.000 description 2
- VFQOCUQGMUXTJR-DCAQKATOSA-N Leu-Cys-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)O)N VFQOCUQGMUXTJR-DCAQKATOSA-N 0.000 description 2
- KGCLIYGPQXUNLO-IUCAKERBSA-N Leu-Gly-Glu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O KGCLIYGPQXUNLO-IUCAKERBSA-N 0.000 description 2
- PNPYKQFJGRFYJE-GUBZILKMSA-N Lys-Ala-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNPYKQFJGRFYJE-GUBZILKMSA-N 0.000 description 2
- KNKHAVVBVXKOGX-JXUBOQSCSA-N Lys-Ala-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KNKHAVVBVXKOGX-JXUBOQSCSA-N 0.000 description 2
- NCTDKZKNBDZDOL-GARJFASQSA-N Lys-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)C(=O)O NCTDKZKNBDZDOL-GARJFASQSA-N 0.000 description 2
- ZAWOJFFMBANLGE-CIUDSAMLSA-N Lys-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)N ZAWOJFFMBANLGE-CIUDSAMLSA-N 0.000 description 2
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 2
- YUAXTFMFMOIMAM-QWRGUYRKSA-N Lys-Lys-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O YUAXTFMFMOIMAM-QWRGUYRKSA-N 0.000 description 2
- YXPJCVNIDDKGOE-MELADBBJSA-N Lys-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N)C(=O)O YXPJCVNIDDKGOE-MELADBBJSA-N 0.000 description 2
- CNGOEHJCLVCJHN-SRVKXCTJSA-N Lys-Pro-Glu Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O CNGOEHJCLVCJHN-SRVKXCTJSA-N 0.000 description 2
- OHXUUQDOBQKSNB-AVGNSLFASA-N Lys-Val-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OHXUUQDOBQKSNB-AVGNSLFASA-N 0.000 description 2
- WGBMNLCRYKSWAR-DCAQKATOSA-N Met-Asp-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN WGBMNLCRYKSWAR-DCAQKATOSA-N 0.000 description 2
- PNHRPOWKRRJATF-IHRRRGAJSA-N Met-Tyr-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 PNHRPOWKRRJATF-IHRRRGAJSA-N 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- BXNGIHFNNNSEOS-UWVGGRQHSA-N Phe-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 BXNGIHFNNNSEOS-UWVGGRQHSA-N 0.000 description 2
- 241000224016 Plasmodium Species 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- OBVCYFIHIIYIQF-CIUDSAMLSA-N Pro-Asn-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O OBVCYFIHIIYIQF-CIUDSAMLSA-N 0.000 description 2
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 2
- IMDMLDSVUSMAEJ-HJGDQZAQSA-N Thr-Leu-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IMDMLDSVUSMAEJ-HJGDQZAQSA-N 0.000 description 2
- YJVJPJPHHFOVMG-VEVYYDQMSA-N Thr-Met-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O YJVJPJPHHFOVMG-VEVYYDQMSA-N 0.000 description 2
- BSCBBPKDVOZICB-KKUMJFAQSA-N Tyr-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BSCBBPKDVOZICB-KKUMJFAQSA-N 0.000 description 2
- WGHVMKFREWGCGR-SRVKXCTJSA-N Val-Arg-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N WGHVMKFREWGCGR-SRVKXCTJSA-N 0.000 description 2
- IRLYZKKNBFPQBW-XGEHTFHBSA-N Val-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)N)O IRLYZKKNBFPQBW-XGEHTFHBSA-N 0.000 description 2
- BEGDZYNDCNEGJZ-XVKPBYJWSA-N Val-Gly-Gln Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O BEGDZYNDCNEGJZ-XVKPBYJWSA-N 0.000 description 2
- KZKMBGXCNLPYKD-YEPSODPASA-N Val-Gly-Thr Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O KZKMBGXCNLPYKD-YEPSODPASA-N 0.000 description 2
- XXROXFHCMVXETG-UWVGGRQHSA-N Val-Gly-Val Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXROXFHCMVXETG-UWVGGRQHSA-N 0.000 description 2
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 2
- 108010081404 acein-2 Proteins 0.000 description 2
- 108010044940 alanylglutamine Proteins 0.000 description 2
- 108010087924 alanylproline Proteins 0.000 description 2
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 108010068380 arginylarginine Proteins 0.000 description 2
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 108010018866 cysteinyl-seryl-valyl-threonyl-cysteinyl-glycine Proteins 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 108010010147 glycylglutamine Proteins 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 108010057952 lysyl-phenylalanyl-lysine Proteins 0.000 description 2
- 108010017391 lysylvaline Proteins 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 108010085203 methionylmethionine Proteins 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108010070643 prolylglutamic acid Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- XAGIMRPOEJSYER-CIUDSAMLSA-N Ala-Cys-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N XAGIMRPOEJSYER-CIUDSAMLSA-N 0.000 description 1
- DUMYKLNEYCJLQK-UHFFFAOYSA-N Ala-Gln-Gln-His Chemical compound CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(=O)NC(C(O)=O)CC1=CN=CN1 DUMYKLNEYCJLQK-UHFFFAOYSA-N 0.000 description 1
- FVSOUJZKYWEFOB-KBIXCLLPSA-N Ala-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N FVSOUJZKYWEFOB-KBIXCLLPSA-N 0.000 description 1
- YJHKTAMKPGFJCT-NRPADANISA-N Ala-Val-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O YJHKTAMKPGFJCT-NRPADANISA-N 0.000 description 1
- JSHVMZANPXCDTL-GMOBBJLQSA-N Arg-Asp-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JSHVMZANPXCDTL-GMOBBJLQSA-N 0.000 description 1
- FBLMOFHNVQBKRR-IHRRRGAJSA-N Arg-Asp-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FBLMOFHNVQBKRR-IHRRRGAJSA-N 0.000 description 1
- UZGFHWIJWPUPOH-IHRRRGAJSA-N Arg-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UZGFHWIJWPUPOH-IHRRRGAJSA-N 0.000 description 1
- RIIVUOJDDQXHRV-SRVKXCTJSA-N Arg-Lys-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O RIIVUOJDDQXHRV-SRVKXCTJSA-N 0.000 description 1
- BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 1
- URAUIUGLHBRPMF-NAKRPEOUSA-N Arg-Ser-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O URAUIUGLHBRPMF-NAKRPEOUSA-N 0.000 description 1
- BWMMKQPATDUYKB-IHRRRGAJSA-N Arg-Tyr-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 BWMMKQPATDUYKB-IHRRRGAJSA-N 0.000 description 1
- LEFKSBYHUGUWLP-ACZMJKKPSA-N Asn-Ala-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LEFKSBYHUGUWLP-ACZMJKKPSA-N 0.000 description 1
- DAPLJWATMAXPPZ-CIUDSAMLSA-N Asn-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(N)=O DAPLJWATMAXPPZ-CIUDSAMLSA-N 0.000 description 1
- BVLIJXXSXBUGEC-SRVKXCTJSA-N Asn-Asn-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BVLIJXXSXBUGEC-SRVKXCTJSA-N 0.000 description 1
- IHUJUZBUOFTIOB-QEJZJMRPSA-N Asn-Gln-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N IHUJUZBUOFTIOB-QEJZJMRPSA-N 0.000 description 1
- FTSAJSADJCMDHH-CIUDSAMLSA-N Asn-Lys-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N FTSAJSADJCMDHH-CIUDSAMLSA-N 0.000 description 1
- WXVGISRWSYGEDK-KKUMJFAQSA-N Asn-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)N WXVGISRWSYGEDK-KKUMJFAQSA-N 0.000 description 1
- BKZFBJYIVSBXCO-KKUMJFAQSA-N Asn-Phe-His Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O BKZFBJYIVSBXCO-KKUMJFAQSA-N 0.000 description 1
- HPASIOLTWSNMFB-OLHMAJIHSA-N Asn-Thr-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O HPASIOLTWSNMFB-OLHMAJIHSA-N 0.000 description 1
- XEGZSHSPQNDNRH-JRQIVUDYSA-N Asn-Tyr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XEGZSHSPQNDNRH-JRQIVUDYSA-N 0.000 description 1
- KRXIWXCXOARFNT-ZLUOBGJFSA-N Asp-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O KRXIWXCXOARFNT-ZLUOBGJFSA-N 0.000 description 1
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 1
- SPWXXPFDTMYTRI-IUKAMOBKSA-N Asp-Ile-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SPWXXPFDTMYTRI-IUKAMOBKSA-N 0.000 description 1
- UJGRZQYSNYTCAX-SRVKXCTJSA-N Asp-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UJGRZQYSNYTCAX-SRVKXCTJSA-N 0.000 description 1
- NVFSJIXJZCDICF-SRVKXCTJSA-N Asp-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N NVFSJIXJZCDICF-SRVKXCTJSA-N 0.000 description 1
- JXGJJQJHXHXJQF-CIUDSAMLSA-N Asp-Met-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O JXGJJQJHXHXJQF-CIUDSAMLSA-N 0.000 description 1
- GIKOVDMXBAFXDF-NHCYSSNCSA-N Asp-Val-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GIKOVDMXBAFXDF-NHCYSSNCSA-N 0.000 description 1
- 241000020089 Atacta Species 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- QADHATDBZXHRCA-ACZMJKKPSA-N Cys-Gln-Asn Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CS)N QADHATDBZXHRCA-ACZMJKKPSA-N 0.000 description 1
- YXPNKXFOBHRUBL-BJDJZHNGSA-N Cys-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N YXPNKXFOBHRUBL-BJDJZHNGSA-N 0.000 description 1
- NIXHTNJAGGFBAW-CIUDSAMLSA-N Cys-Lys-Ser Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N NIXHTNJAGGFBAW-CIUDSAMLSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- INFBPLSHYFALDE-ACZMJKKPSA-N Gln-Asn-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O INFBPLSHYFALDE-ACZMJKKPSA-N 0.000 description 1
- PNENQZWRFMUZOM-DCAQKATOSA-N Gln-Glu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O PNENQZWRFMUZOM-DCAQKATOSA-N 0.000 description 1
- DWDBJWAXPXXYLP-SRVKXCTJSA-N Gln-His-Arg Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N DWDBJWAXPXXYLP-SRVKXCTJSA-N 0.000 description 1
- TYRMVTKPOWPZBC-SXNHZJKMSA-N Gln-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCC(=O)N)N TYRMVTKPOWPZBC-SXNHZJKMSA-N 0.000 description 1
- PAOHIZNRJNIXQY-XQXXSGGOSA-N Gln-Thr-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PAOHIZNRJNIXQY-XQXXSGGOSA-N 0.000 description 1
- OEIDWQHTRYEYGG-QEJZJMRPSA-N Gln-Trp-Asp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N OEIDWQHTRYEYGG-QEJZJMRPSA-N 0.000 description 1
- YMCPEHDGTRUOHO-SXNHZJKMSA-N Gln-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)N)N YMCPEHDGTRUOHO-SXNHZJKMSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- GLWXKFRTOHKGIT-ACZMJKKPSA-N Glu-Asn-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GLWXKFRTOHKGIT-ACZMJKKPSA-N 0.000 description 1
- CUXJIASLBRJOFV-LAEOZQHASA-N Glu-Gly-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CUXJIASLBRJOFV-LAEOZQHASA-N 0.000 description 1
- UGSVSNXPJJDJKL-SDDRHHMPSA-N Glu-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N UGSVSNXPJJDJKL-SDDRHHMPSA-N 0.000 description 1
- OQXDUSZKISQQSS-GUBZILKMSA-N Glu-Lys-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OQXDUSZKISQQSS-GUBZILKMSA-N 0.000 description 1
- OHWJUIXZHVIXJJ-GUBZILKMSA-N Glu-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N OHWJUIXZHVIXJJ-GUBZILKMSA-N 0.000 description 1
- SUIAHERNFYRBDZ-GVXVVHGQSA-N Glu-Lys-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O SUIAHERNFYRBDZ-GVXVVHGQSA-N 0.000 description 1
- QOXDAWODGSIDDI-GUBZILKMSA-N Glu-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N QOXDAWODGSIDDI-GUBZILKMSA-N 0.000 description 1
- ZTNHPMZHAILHRB-JSGCOSHPSA-N Glu-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)NCC(O)=O)=CNC2=C1 ZTNHPMZHAILHRB-JSGCOSHPSA-N 0.000 description 1
- RMWAOBGCZZSJHE-UMNHJUIQSA-N Glu-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N RMWAOBGCZZSJHE-UMNHJUIQSA-N 0.000 description 1
- SOYWRINXUSUWEQ-DLOVCJGASA-N Glu-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O SOYWRINXUSUWEQ-DLOVCJGASA-N 0.000 description 1
- CLODWIOAKCSBAN-BQBZGAKWSA-N Gly-Arg-Asp Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(O)=O)C(O)=O CLODWIOAKCSBAN-BQBZGAKWSA-N 0.000 description 1
- XBWMTPAIUQIWKA-BYULHYEWSA-N Gly-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN XBWMTPAIUQIWKA-BYULHYEWSA-N 0.000 description 1
- RPLLQZBOVIVGMX-QWRGUYRKSA-N Gly-Asp-Phe Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RPLLQZBOVIVGMX-QWRGUYRKSA-N 0.000 description 1
- CQZDZKRHFWJXDF-WDSKDSINSA-N Gly-Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CN CQZDZKRHFWJXDF-WDSKDSINSA-N 0.000 description 1
- ZQIMMEYPEXIYBB-IUCAKERBSA-N Gly-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN ZQIMMEYPEXIYBB-IUCAKERBSA-N 0.000 description 1
- HMHRTKOWRUPPNU-RCOVLWMOSA-N Gly-Ile-Gly Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O HMHRTKOWRUPPNU-RCOVLWMOSA-N 0.000 description 1
- COVXELOAORHTND-LSJOCFKGSA-N Gly-Ile-Val Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O COVXELOAORHTND-LSJOCFKGSA-N 0.000 description 1
- PTIIBFKSLCYQBO-NHCYSSNCSA-N Gly-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CN PTIIBFKSLCYQBO-NHCYSSNCSA-N 0.000 description 1
- MHZXESQPPXOING-KBPBESRZSA-N Gly-Lys-Phe Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MHZXESQPPXOING-KBPBESRZSA-N 0.000 description 1
- JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 description 1
- DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 1
- SVHKVHBPTOMLTO-DCAQKATOSA-N His-Arg-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SVHKVHBPTOMLTO-DCAQKATOSA-N 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- LEDRIAHEWDJRMF-CFMVVWHZSA-N Ile-Asn-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LEDRIAHEWDJRMF-CFMVVWHZSA-N 0.000 description 1
- MTONDYJJCIBZTK-PEDHHIEDSA-N Ile-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)O)N MTONDYJJCIBZTK-PEDHHIEDSA-N 0.000 description 1
- TVYWVSJGSHQWMT-AJNGGQMLSA-N Ile-Leu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N TVYWVSJGSHQWMT-AJNGGQMLSA-N 0.000 description 1
- FJWALBCCVIHZBS-QXEWZRGKSA-N Ile-Met-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)O)N FJWALBCCVIHZBS-QXEWZRGKSA-N 0.000 description 1
- WXLYNEHOGRYNFU-URLPEUOOSA-N Ile-Thr-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N WXLYNEHOGRYNFU-URLPEUOOSA-N 0.000 description 1
- XVUAQNRNFMVWBR-BLMTYFJBSA-N Ile-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N XVUAQNRNFMVWBR-BLMTYFJBSA-N 0.000 description 1
- APQYGMBHIVXFML-OSUNSFLBSA-N Ile-Val-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N APQYGMBHIVXFML-OSUNSFLBSA-N 0.000 description 1
- DBVWMYGBVFCRBE-CIUDSAMLSA-N Leu-Asn-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O DBVWMYGBVFCRBE-CIUDSAMLSA-N 0.000 description 1
- LAPSXOAUPNOINL-YUMQZZPRSA-N Leu-Gly-Asp Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O LAPSXOAUPNOINL-YUMQZZPRSA-N 0.000 description 1
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 1
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 1
- JLWZLIQRYCTYBD-IHRRRGAJSA-N Leu-Lys-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JLWZLIQRYCTYBD-IHRRRGAJSA-N 0.000 description 1
- ZGUMORRUBUCXEH-AVGNSLFASA-N Leu-Lys-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZGUMORRUBUCXEH-AVGNSLFASA-N 0.000 description 1
- LVTJJOJKDCVZGP-QWRGUYRKSA-N Leu-Lys-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O LVTJJOJKDCVZGP-QWRGUYRKSA-N 0.000 description 1
- BGZCJDGBBUUBHA-KKUMJFAQSA-N Leu-Lys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O BGZCJDGBBUUBHA-KKUMJFAQSA-N 0.000 description 1
- PWPBLZXWFXJFHE-RHYQMDGZSA-N Leu-Pro-Thr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O PWPBLZXWFXJFHE-RHYQMDGZSA-N 0.000 description 1
- JGKHAFUAPZCCDU-BZSNNMDCSA-N Leu-Tyr-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=C(O)C=C1 JGKHAFUAPZCCDU-BZSNNMDCSA-N 0.000 description 1
- XZNJZXJZBMBGGS-NHCYSSNCSA-N Leu-Val-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XZNJZXJZBMBGGS-NHCYSSNCSA-N 0.000 description 1
- SJNZALDHDUYDBU-IHRRRGAJSA-N Lys-Arg-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(O)=O SJNZALDHDUYDBU-IHRRRGAJSA-N 0.000 description 1
- DGAAQRAUOFHBFJ-CIUDSAMLSA-N Lys-Asn-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O DGAAQRAUOFHBFJ-CIUDSAMLSA-N 0.000 description 1
- WGCKDDHUFPQSMZ-ZPFDUUQYSA-N Lys-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN WGCKDDHUFPQSMZ-ZPFDUUQYSA-N 0.000 description 1
- QIJVAFLRMVBHMU-KKUMJFAQSA-N Lys-Asp-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QIJVAFLRMVBHMU-KKUMJFAQSA-N 0.000 description 1
- RDIILCRAWOSDOQ-CIUDSAMLSA-N Lys-Cys-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N RDIILCRAWOSDOQ-CIUDSAMLSA-N 0.000 description 1
- QFGVDCBPDGLVTA-SZMVWBNQSA-N Lys-Gln-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCCN)C(O)=O)=CNC2=C1 QFGVDCBPDGLVTA-SZMVWBNQSA-N 0.000 description 1
- KYNNSEJZFVCDIV-ZPFDUUQYSA-N Lys-Ile-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O KYNNSEJZFVCDIV-ZPFDUUQYSA-N 0.000 description 1
- WVJNGSFKBKOKRV-AJNGGQMLSA-N Lys-Leu-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVJNGSFKBKOKRV-AJNGGQMLSA-N 0.000 description 1
- VUTWYNQUSJWBHO-BZSNNMDCSA-N Lys-Leu-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O VUTWYNQUSJWBHO-BZSNNMDCSA-N 0.000 description 1
- ZJWIXBZTAAJERF-IHRRRGAJSA-N Lys-Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N ZJWIXBZTAAJERF-IHRRRGAJSA-N 0.000 description 1
- RIJCHEVHFWMDKD-SRVKXCTJSA-N Lys-Lys-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O RIJCHEVHFWMDKD-SRVKXCTJSA-N 0.000 description 1
- LMGNWHDWJDIOPK-DKIMLUQUSA-N Lys-Phe-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LMGNWHDWJDIOPK-DKIMLUQUSA-N 0.000 description 1
- MEQLGHAMAUPOSJ-DCAQKATOSA-N Lys-Ser-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O MEQLGHAMAUPOSJ-DCAQKATOSA-N 0.000 description 1
- QFSYGUMEANRNJE-DCAQKATOSA-N Lys-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N QFSYGUMEANRNJE-DCAQKATOSA-N 0.000 description 1
- XABXVVSWUVCZST-GVXVVHGQSA-N Lys-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN XABXVVSWUVCZST-GVXVVHGQSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- FGXIJNMDRCZVDE-KKUMJFAQSA-N Phe-Cys-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N FGXIJNMDRCZVDE-KKUMJFAQSA-N 0.000 description 1
- JEBWZLWTRPZQRX-QWRGUYRKSA-N Phe-Gly-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O JEBWZLWTRPZQRX-QWRGUYRKSA-N 0.000 description 1
- QPVFUAUFEBPIPT-CDMKHQONSA-N Phe-Gly-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O QPVFUAUFEBPIPT-CDMKHQONSA-N 0.000 description 1
- SCKXGHWQPPURGT-KKUMJFAQSA-N Phe-Lys-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O SCKXGHWQPPURGT-KKUMJFAQSA-N 0.000 description 1
- 235000011612 Pinus armandii Nutrition 0.000 description 1
- 240000000793 Pinus armandii Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 101900073696 Plasmodium vivax Duffy receptor Proteins 0.000 description 1
- 201000009976 Plasmodium vivax malaria Diseases 0.000 description 1
- RMODQFBNDDENCP-IHRRRGAJSA-N Pro-Lys-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O RMODQFBNDDENCP-IHRRRGAJSA-N 0.000 description 1
- HWLKHNDRXWTFTN-GUBZILKMSA-N Pro-Pro-Cys Chemical compound C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CS)C(=O)O HWLKHNDRXWTFTN-GUBZILKMSA-N 0.000 description 1
- CWZUFLWPEFHWEI-IHRRRGAJSA-N Pro-Tyr-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O CWZUFLWPEFHWEI-IHRRRGAJSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 1
- LWMQRHDTXHQQOV-MXAVVETBSA-N Ser-Ile-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LWMQRHDTXHQQOV-MXAVVETBSA-N 0.000 description 1
- GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 1
- GSCVDSBEYVGMJQ-SRVKXCTJSA-N Ser-Tyr-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CO)N)O GSCVDSBEYVGMJQ-SRVKXCTJSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
- GFDUZZACIWNMPE-KZVJFYERSA-N Thr-Ala-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O GFDUZZACIWNMPE-KZVJFYERSA-N 0.000 description 1
- SKHPKKYKDYULDH-HJGDQZAQSA-N Thr-Asn-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SKHPKKYKDYULDH-HJGDQZAQSA-N 0.000 description 1
- JBHMLZSKIXMVFS-XVSYOHENSA-N Thr-Asn-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JBHMLZSKIXMVFS-XVSYOHENSA-N 0.000 description 1
- GNHRVXYZKWSJTF-HJGDQZAQSA-N Thr-Asp-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O GNHRVXYZKWSJTF-HJGDQZAQSA-N 0.000 description 1
- APIQKJYZDWVOCE-VEVYYDQMSA-N Thr-Asp-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O APIQKJYZDWVOCE-VEVYYDQMSA-N 0.000 description 1
- XDARBNMYXKUFOJ-GSSVUCPTSA-N Thr-Asp-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XDARBNMYXKUFOJ-GSSVUCPTSA-N 0.000 description 1
- BNGDYRRHRGOPHX-IFFSRLJSSA-N Thr-Glu-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O BNGDYRRHRGOPHX-IFFSRLJSSA-N 0.000 description 1
- WRQLCVIALDUQEQ-UNQGMJICSA-N Thr-Phe-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WRQLCVIALDUQEQ-UNQGMJICSA-N 0.000 description 1
- YGZWVPBHYABGLT-KJEVXHAQSA-N Thr-Pro-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YGZWVPBHYABGLT-KJEVXHAQSA-N 0.000 description 1
- IJKNKFJZOJCKRR-GBALPHGKSA-N Thr-Trp-Ser Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 IJKNKFJZOJCKRR-GBALPHGKSA-N 0.000 description 1
- IXEGQBJZDIRRIV-QEJZJMRPSA-N Trp-Asn-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IXEGQBJZDIRRIV-QEJZJMRPSA-N 0.000 description 1
- BONYBFXWMXBAND-GQGQLFGLSA-N Trp-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N BONYBFXWMXBAND-GQGQLFGLSA-N 0.000 description 1
- YDTKYBHPRULROG-LTHWPDAASA-N Trp-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N YDTKYBHPRULROG-LTHWPDAASA-N 0.000 description 1
- BOBZBMOTRORUPT-XIRDDKMYSA-N Trp-Ser-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O)=CNC2=C1 BOBZBMOTRORUPT-XIRDDKMYSA-N 0.000 description 1
- YCQXZDHDSUHUSG-FJHTZYQYSA-N Trp-Thr-Ala Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O)=CNC2=C1 YCQXZDHDSUHUSG-FJHTZYQYSA-N 0.000 description 1
- WXEQUSQNDDJEDZ-NYVOZVTQSA-N Trp-Trp-Asn Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(=O)N)C(=O)O)N WXEQUSQNDDJEDZ-NYVOZVTQSA-N 0.000 description 1
- DYEGCOJHFNJBKB-UFYCRDLUSA-N Tyr-Arg-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 DYEGCOJHFNJBKB-UFYCRDLUSA-N 0.000 description 1
- GAYLGYUVTDMLKC-UWJYBYFXSA-N Tyr-Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GAYLGYUVTDMLKC-UWJYBYFXSA-N 0.000 description 1
- IXTQGBGHWQEEDE-AVGNSLFASA-N Tyr-Asp-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 IXTQGBGHWQEEDE-AVGNSLFASA-N 0.000 description 1
- QFXVAFIHVWXXBJ-AVGNSLFASA-N Tyr-Ser-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O QFXVAFIHVWXXBJ-AVGNSLFASA-N 0.000 description 1
- RVGVIWNHABGIFH-IHRRRGAJSA-N Tyr-Val-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O RVGVIWNHABGIFH-IHRRRGAJSA-N 0.000 description 1
- BYOHPUZJVXWHAE-BYULHYEWSA-N Val-Asn-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N BYOHPUZJVXWHAE-BYULHYEWSA-N 0.000 description 1
- XIFAHCUNWWKUDE-DCAQKATOSA-N Val-Cys-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N XIFAHCUNWWKUDE-DCAQKATOSA-N 0.000 description 1
- VVZDBPBZHLQPPB-XVKPBYJWSA-N Val-Glu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O VVZDBPBZHLQPPB-XVKPBYJWSA-N 0.000 description 1
- BTWMICVCQLKKNR-DCAQKATOSA-N Val-Leu-Ser Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C([O-])=O BTWMICVCQLKKNR-DCAQKATOSA-N 0.000 description 1
- YMTOEGGOCHVGEH-IHRRRGAJSA-N Val-Lys-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O YMTOEGGOCHVGEH-IHRRRGAJSA-N 0.000 description 1
- DOFAQXCYFQKSHT-SRVKXCTJSA-N Val-Pro-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DOFAQXCYFQKSHT-SRVKXCTJSA-N 0.000 description 1
- VIKZGAUAKQZDOF-NRPADANISA-N Val-Ser-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O VIKZGAUAKQZDOF-NRPADANISA-N 0.000 description 1
- NLNCNKIVJPEFBC-DLOVCJGASA-N Val-Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O NLNCNKIVJPEFBC-DLOVCJGASA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000005469 Vivax Malaria Diseases 0.000 description 1
- 238000010817 Wright-Giemsa staining Methods 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000019469 detection of protozoan Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010087823 glycyltyrosine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 108010027338 isoleucylcysteine Proteins 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 229940124735 malaria vaccine Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 238000000765 microspectrophotometry Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940118768 plasmodium malariae Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000001563 schizont Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000011120 smear test Methods 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6893—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 삼일열 말라리아(Plasml dium vivax)의 유전자, 그에 의해 코딩되는 펩티드, 및 이를 이용한 삼일열 말라리아의 검출방법에 관한 것이고. 보다 상세하게는 삼일열 말라리아의 표면에 발현되는 특정 단백을 코딩하는 유전자, 이에 코딩되는 펩티드 및 이를 이용하여 정확하고 신속하게 삼일열 말라리아를 검출하는 방법에 관한 것이다.The present invention relates to a gene of Plasml dium vivax, a peptide encoded by the same, and a method for detecting triple row malaria using the same. More specifically, the present invention relates to a gene encoding a specific protein expressed on the surface of trigeminal malaria, a peptide encoded therein, and a method for accurately and rapidly detecting trigeminal malaria using the same.
말라리아는 고대부터 존재하던 인류 최대의 질환으로 20세기 이후 사람 적혈구에서 원충이 처음 발견된 후 많은 노력에도 불구하고 오늘날까지 사라지지 않고 더욱 약화되지 않는 인류의 주 관심 대상이고 지구 전체의 세계적인 문제로 등장하고 있는 실정이다. 그리고 불행하게도 60년대 이후 한국을 포함하여 말라리아 유행이 사라진 지역에서도 재등장이 보고되고 있다.Malaria is the largest human disease that has existed since ancient times, and since the first discovery of protozoa in human erythrocytes since the 20th century, despite many efforts, it is the main concern of mankind that does not disappear and becomes weaker even today. I'm doing it. Unfortunately, re-emergence has also been reported in areas where the malaria epidemic has disappeared, including Korea since the 1960s.
말라리아는 적혈구나 간 세포 내에 포자충강(class Sporozoa)의 Plasmodium속에 속하는 원충이 일으키는 질병이다. 사람에게 발생하는 말라리아는 열대열 말라리아(Plasmodium falciparum), 삼일열 말라리라(Plasml dium vivax), 사일열 말라리아(Plasmodium malariae)와 난형 말라리아(Plasmodium ovale)의 네 종류가 있는데, 이 네 가지 말라리아 중 처음의 두 종류가 전세계에서 발생하는 말라리아환자의 95%이상을 차지하며, 우리나라에서 최근 발생한 말라리아는 모두 삼일열 말라리아(Plasmodium vivax)이었다.Malaria is a disease caused by protozoans belonging to the genus Plasmodium of the class Sporozoa in red blood cells or liver cells. There are four types of malaria that occur in humans: Plasmodium falciparum, Plasml dium vivax, Plasmodium malariae, and Plasmodium ovale. Two types account for more than 95% of malaria cases worldwide, and the latest malaria cases in Korea were all three days of malaria (Plasmodium vivax).
기존 말라리아 감염의 진단은 혈액 도말 검사를 통한 혈중 원충 발견으로 이루어진다. 말라리아는 풍토병지역에서 모든 발열환자의 혈액을 대상으로 검사되어져야 하고, 열대지방을 몇 시간 경유하는 경우에라도 발열이 난다면 말라리아를 의심해야 한다. 임상적인 증상으로는 말라리아가 의심됨에도 불구하고 혈액 도말 검사를 할 시설이 없거나 즉시 검사결과를 알 수 없을 때에는 임시로 약제를 투여할 수 있다. 그러나, 이 경우에도 감염확인을 위하여 치료 전에 혈액 도말 검체를 확보해두어야 한다. 말라리아 약제를 투여하여도 발열이 조절되지 않는다면 다른 발열 원인을 생각해야 하며, 아프리카의 말라리아 풍토병 지역에서는 임상적 증상으로 말라리아가 의심되지만 현미경 검사상 원충을 확인할 수 없는 경우가 거의 절반에 이르는데, 이는 감염이 적은 경우이다.The diagnosis of an existing malaria infection consists in the detection of protozoa in the blood through blood smear testing. Malaria should be tested for blood in all fever patients in endemic areas, and suspected malaria if fever occurs even after several hours in the tropics. The clinical symptom may be a temporary medication if malaria is suspected and there is no facility to perform blood smear testing or the results are not immediately available. However, even in this case, a blood smear should be obtained before treatment to confirm infection. If malaria medications do not control fever, other causes of fever should be considered.In Africa, malaria is suspected of being a clinical symptom in malaria endemic areas. There is little infection.
이외에 말라리아에 대한 간접형광항체검사(Indirect Fluorescent Antibody Test : IFAT)가 개발되어, 과거에 있었던 말라리아 감염과 함께 적은 감염도 확인할 수 있는 검사방법으로서 역학 조사목적으로 이용된다. 또한 말라리아 비장비대증의 진단과 혈액의 말라리아 선별검사에도 이용된다. IFAT에서 사용하는 균질 항원은 사람, 원숭이, 실험적 혈액배양에서 얻는 적혈구 쉬존트(schizont)에서 얻는다. 먼저 IFAT검사 슬라이드에 항원, 항-인간 글로블린과 형광 이소티오시아네이트가 있고, 거기에 희석된 검체 항체가 반응한 결과를 형광현미경으로 확인하는 것이다. 이 검사는 말라리아의 면역반응결과를 확인하는 것이지 반드시 말라리아 원충이 있어야 하는 것은 아니다. 역가(titer)가 1:200이상이면 최근 감염이 의심되며, 1:20이상이면 양성반응으로 간주된다.In addition, the Indirect Fluorescent Antibody Test (IFAT) has been developed for malaria and is used for epidemiological investigation as a test that can identify small infections with past malaria infections. It is also used for the diagnosis of malarial paralysis and for screening malaria in the blood. Homogeneous antigens used in IFAT are obtained from erythrocyte Schizont from humans, monkeys, and experimental blood cultures. First, there is an antigen, anti-human globulin, and fluorescent isothiocyanate on the IFAT test slide, and the result of the reaction of the diluted sample antibody is confirmed by the fluorescence microscope. This test confirms the results of malaria's immune response, not necessarily malaria parasites. A titer of greater than 1: 200 is suspected of a recent infection, and a titer of greater than 1:20 is considered positive.
이상과 같은 종래의 말라리아 검출방법은 다음과 같은 문제점을 갖고 있다. 먼저 말초혈액 도말 검사는 말초혈액 도말을 환자에서 실시하여 염색을 실시한 후 현미경으로 검사하는 방법으로, 검사 시간이 많이 소모될 뿐 아니라 검사결과를 숙련된 의사에 의해서 확인해야 하는 번거로움이 있고, 대량의 검사에는 적당하지 않다. 또한 말라리아 원충이 적은 경우에는 확인이 어렵고 말라리아의 과거 감염 여부를 확인 할 수 없어 말라리아 감염후 휴지기(hypnotic) 상태의 불현성 감염을 알 수가 없다. 더구나 말라리아 균종 간에 형태학적으로 유사성이 높아 이들 균종을 서로 구분하기 어려운 문제점도 있다.The conventional malaria detection method as described above has the following problems. First, the peripheral blood smear test is a method of performing peripheral blood smear in a patient and staining it, and then examining it under a microscope. In addition, a lot of test time is consumed, and the result of a test is checked by an experienced doctor. It is not suitable for inspection. In addition, it is difficult to identify if there are few malaria protozoa, and it is not possible to confirm the past infection of malaria. In addition, there is a problem in that it is difficult to distinguish these species from each other because of high morphological similarity between malaria species.
현재 사용하는 간접 면역 형광법(Indirect Immunofluorescence test)은 환자의 혈청을 이용하여 말라리아 항체를 찾아내는 것으로 고가의 형광 현미경을 사용해야 하며 판독에 객관적인 기준이 없어, 검사 결과를 숙련된 의사에 의해서 확인해야 하는 번거로움이 있고, 대량의 검사에는 적당하지 않다. 또한 말라리아의 과거 감염여부를 확인 할 수 있으나 현재 원숭이가 아닌 사람의 감염 혈액으로 제조하는 경우 위양성율(僞陽性率)이 높아 검사의 문제점이 있다.Indirect Immunofluorescence test is currently used to detect malaria antibody using patient's serum. It requires expensive fluorescence microscope and there is no objective standard for reading. There is, and it is not suitable for mass inspection. In addition, it is possible to check the past infection of malaria, but the current false positive rate (僞 陽性 率) when manufactured with infected blood of non-monkeys have a problem of testing.
따라서 본 발명의 목적은 보다 정확하고 신속하게 말라리아를 검출할 수 있는 수단을 제공하는 것이다.It is therefore an object of the present invention to provide a means for detecting malaria more accurately and quickly.
본 발명은 서열번호 1로 나타내지는 삼일열 말라리아의 분열소체 표면 단백(merozoite surface protein)을 코딩하는 유전자를 제공한다.The present invention provides a gene encoding the merozoite surface protein of trigeminal malaria represented by SEQ ID NO: 1.
본 발명은 서열번호 2로 나타내지는 삼일열 말라리아의 분열소체 표면 단백을 제공한다.The present invention provides a cleavage surface protein of triplet malaria represented by SEQ ID NO: 2.
본 발명은 또한 상기 단백을 이용하여 보다 정확하고, 감도높고 신속하게 삼일열 말라리아를 검출하는 방법을 제공한다.The present invention also provides a method for detecting triplet malaria more accurately, sensitively and quickly using the protein.
도 1는 삼일열 말라리아의 분열소체 표면 단백(MSP)을 코딩하는 유전자를 분리하기 위한 전기영동의 결과를 보여준다.Figure 1 shows the results of electrophoresis to isolate genes encoding fissile surface proteins (MSPs) of febrile malaria.
도 2는 삼일열 말라리아의 서컴스포로조이트 표면 단백(CSP)을 코딩하는 유전자를 분리하기 위한 전기영동의 결과를 보여준다.FIG. 2 shows the results of electrophoresis to isolate genes encoding circus sporozoite surface protein (CSP) of febrile malaria.
한국형 말라리아의 표면 단백(surface protein)의 유전자형을 밝혀낸다면 이 유전자로 유전공학을 이용하여 재조합 단백을 만들 수 있고 이 유전자는 말라리아의 예방을 위한 진단시약, 특히 간편한 방법인 효소면역검사를 할 수 있는 원료 항원이 된다. 또한 이 항원을 이용하여 말라리아 백신을 개발할 수 있으므로 말라리아의 간단한 진단 및 예방, 역학적 연구에 결정적인 역할을 할 수 있다. 이 개발된 말라리아 항원을 이용하여 진단시약과 백신을 제조하려면 이 유전자를 기초로 한 단백질 발현 과정이 필요하다.If the genotype of the surface protein of Korean malaria is identified, this gene can be used to make recombinant protein using genetic engineering, and this gene can be used as a diagnostic reagent for preventing malaria, especially enzyme immunoassay which is a convenient method. It becomes a raw antigen. The antigen can also be used to develop malaria vaccines, which can play a crucial role in the simple diagnosis, prevention and epidemiological studies of malaria. The production of diagnostic reagents and vaccines using this developed malaria antigen requires a protein expression process based on this gene.
본 발명은 말라리아가 처음 인체에 침입시 간세포에 부착하는 기능을 하는 서컴스포로조이트(Circumsporozoite) 단백과 더불어 말라리아가 증식하면서 인접 적혈구를 침입할 때 가장 중요한 기능에 관여하는 분열소체 표면 단백 및 Duffy 혈액형 부착 단백을 코딩하는 유전자, 이 유전자에 의해 코딩되는 단백을 제공한다. 이들 단백은 사람에서 말라리아에 대한 감염을 방지하는 면역기능을 형성하는데 중요한 기능을 하고 있다. 따라서 이 단백질을 항원으로 이용하여 말라리아-검출용 면역 효소검사시약 및 말라리아 백신을 개발할 수 있다.The present invention relates to circumsporozoite protein, which functions to attach to liver cells when malaria first invades the human body, as well as mitotic surface protein and Duffy, which are involved in the most important function when malaria proliferates and invades adjacent red blood cells. Genes encoding blood type adhesion proteins, proteins encoded by these genes are provided. These proteins play an important role in forming immune functions that prevent malaria infection in humans. Therefore, this protein can be used as an antigen to develop malaria-detecting immunoenzyme reagent and malaria vaccine.
이하 본 발명을 실시하기 위한 실험 방법 및 그 결과를 상세히 설명한다.Hereinafter, an experimental method for carrying out the present invention and the results thereof will be described in detail.
1.연구대상1. Research subject
1996년에서 1997년 사이 국군수도병원과 고려대학교 임상병리과학 교실에 말라리아의 특징적인 증상을 보여 내원하거나 검체가 의뢰된 환자 50명을 대상으로 혈액 도말 검사를 실시하여 원충의 존재를 확진한 뒤 직접 병력조사를 통해 국내발생 말라리아로 추정되는 예를 대상으로 하였으며 혈액검사 등을 통해 혈중의 원충농도와 발생환자의 역학적인 상황을 조사하였다.Between 1996 and 1997, the Department of Clinical Pathology and the Department of Clinical Pathology in Korea University showed the symptoms of malaria, and blood smears were performed on 50 patients who were referred or referred for confirmation. The history of malaria was estimated through the history of the disease, and the protozoa concentration in the blood and the epidemiological status of the incidence patients were examined through blood tests.
2.연구방법2. Research method
1) 임상진단1) Clinical diagnosis
환자의 임상적인 진단은 삼일열 말라리아의 특이 증상을 보이는 환자에서 개별적인 면담을 통해 증상의 발병 일시, 근무 장소, 발열 양상 및 간격, 해외여행 여부 등을 조사하였고 혈액 도말검사를 통해 원충의 존재를 확인하여 분석하였다.The clinical diagnosis of patients with peculiar symptoms of trigeminal fever malaria examined the onset of symptoms, the place of work, the pattern and interval of fever, and whether they were traveling abroad, and confirmed the presence of protozoa through blood smears. And analyzed.
2) 말라리아의 형태학적 진단 및 혈중 농도의 계산2) Morphological diagnosis of malaria and calculation of blood concentration
말라리아의 형태학적인 진단은 EDTA가 들어있는 진공채혈관 (Becton- Dickinson, 미국)을 사용하여 전박 주정맥에서 4-5mL의 정맥혈을 채혈한 뒤 유리 슬라이드에 박층 혈액 도말(thin blood smear)과 후층 도말(thick blood smear)을 동시에 준비하여 Wright-Giemsa 염색법과 Giemsa 염색법으로 말초 혈액 도말검사를 실시하였다. 원충의 존재는 말라리아의 원충 단계에 따라 존재 유무를 표기하였으며 자동 혈구 분석기 (Celldyne 3000, 미국)에서 측정된 백혈구 수를 이용하여 현미경 검경시 계수된 백혈구 수 대비 말라리아 원충의 수로 환산하였다. 자세한 계산방식은 아래와 같다.Morphological diagnosis of malaria involves the use of a vacuum vessel containing EDTA (Becton-Dickinson, USA) to draw 4-5 mL of venous blood from the forearm vein, followed by a thin blood smear and a thick layer smear on a glass slide. Thick blood smears were prepared at the same time and peripheral blood smears were performed by Wright-Giemsa staining and Giemsa staining. The presence of protozoa was indicated according to the stage of protozoa of malaria, and converted into the number of malaria protozoans compared to the count of white blood cells at the time of microscopic examination using the white blood cell count measured by an automated hemocytometer (Celldyne 3000, USA). Detailed calculation method is as follows.
말라리아 혈중 원충농도(Parasite/㎕)Malaria Blood Protozoal Concentration (Parasite / μl)
= 백혈구 100개당 원충 수 x 단위 용적당 백혈구 수(/㎕) / 100= Number of protozoans per 100 leukocytes x leukocytes per unit volume (/ μl) / 100
3) 중합효소 연쇄반응3) polymerase chain reaction
(1) DNA 추출과정(1) DNA extraction process
채혈된 전혈로 부터 DNA 추출 키트(InstaGeneTMMatrix)를 이용하여 DNA를 추출하였다. DNA 추출 방법은 증류수 1mL에 전혈 10 ㎕를 더한 후 실온에서 30분간 방치한 다음 12,000 RPM에서 3분간 원침한 후 20 ㎕의 상층액만 남기고 조심스럽게 따라버린다. 남은 침전물에 DNA 추출용액 (InstaGeneTMMatrix) 200 ㎕를 가한 후 56℃ 히트 블록(heat block)에 30분간 둔 다음 10초간 볼텍스로 강하게 진탕한 뒤 100℃ 히트 블록에 8분간 둔다. 다시 볼텍스로 10초간 강하게 진탕한 후 12,000 RPM에 3분간 침전하면 보유액에 DNA가 추출된다.DNA was extracted from the collected whole blood using a DNA extraction kit (InstaGene ™ Matrix). In the DNA extraction method, 10 μl of whole blood is added to 1 mL of distilled water, left at room temperature for 30 minutes, and then immersed for 3 minutes at 12,000 RPM, followed by carefully, leaving only 20 μl of supernatant. 200 μl of DNA extraction solution (InstaGene TM Matrix) was added to the remaining precipitate, and then placed in a 56 ° C. heat block for 30 minutes, followed by vigorous shaking with a vortex for 10 seconds, followed by 8 minutes in a 100 ° C. heat block. After vigorously shaking with vortex for 10 seconds, it was precipitated at 12,000 RPM for 3 minutes to extract DNA from the holding solution.
(2) 중합효소연쇄반응(2) polymerase chain reaction
추출된 DNA의 증폭은 GeneAmp PCR system 9600( Perkin Elmer, 미국)을 이용한 중합효소연쇄반응(PCR)에 의해 수행하였다. 각 단백의 PCR 프라이머로서, 서컴스포로조이트 단백은 염기서열 번호 (SEQ ID NO:) 7과 8의 서열, 분열소체 표면 단백은 염기서열 번호 (SEQ ID NO:) 9와 10의 서열, 그리고 더피(Duffy) 결합 단백은 염기서열 번호 (SEQ ID NO:) 11과 12의 서열로 표시한 것을 각각 이용하였다.Amplification of the extracted DNA was performed by polymerase chain reaction (PCR) using a GeneAmp PCR system 9600 (Perkin Elmer, USA). As PCR primers for each protein, the circus sporozoite protein has the sequences of SEQ ID NOs: 7 and 8, the cleavage surface protein has the sequences of SEQ ID NOs: 9 and 10, and Duffy (Duffy) binding protein was used as the sequence represented by the sequence of SEQ ID NO: 11 and 12, respectively.
이들 프라이머들은 각각 약 700-1000bp의 반응산물을 만들도록 본 발명자가 고안한 것들이다. 중합효소연쇄반응시 반응 검체의 혼합 조건은 프라이머의 농도를 각각 1 pmol/㎕로, MgCl2의 농도는 20 μmol/㎕ 조절하였다.These primers are each designed by the inventors to make a reaction product of about 700-1000bp each. In the polymerase chain reaction, the mixing conditions of the reaction samples were adjusted to 1 pmol / μl of primer concentration and 20 μmol / μl of MgCl 2 .
중합 연쇄효소반응은 95℃에서 1분간 열 변성을 시킨 뒤 53℃에서 1분간 결합시킨 뒤 72℃에서 3분간 중합 반응을 시켜 30주기를 반응시켰으며 반응산물의 검출 및 확인은 중합 연쇄반응의 반응 산물 10 ㎕를 2% 아가로스 겔에 전기영동 시켜 에티디움 브로마이드(ethidium bromide)로 염색하여 염기 띠를 확인하였다.The polymerase chain reaction was thermally denatured at 95 ° C. for 1 minute, then bound at 53 ° C. for 1 minute, and then polymerized at 72 ° C. for 3 minutes to react 30 cycles. 10 μl of the product was electrophoresed on a 2% agarose gel and stained with ethidium bromide to confirm base bands.
(3) 염기서열 결정(3) base sequence determination
중폭된 DNA의 염기서열 결정은 ABI PRISMTMDye Terminator Cycle Sequencing Ready Reaction Kit(Perkin Elmer)를 사용하여 반응액 20㎕당 종결 반응혼합물(Terminator Ready Reaction Mix) 8㎕, 1μM 프라이머 3.2㎕ 와 30 100ng의 주형( template)을 첨가하고 광유를 가하여 열 사이클러(thermal cycler)로 25회 주기로 증폭하였다. 증폭에 사용하는 주기는 96℃ 30초, 50℃ 15초, 60℃ 4분이며 첫번째 주기는 96℃ 5분을 채택하였다. 증폭 종료 후에는 반응액을 3M 초산나트륨(pH 4.6) 2㎕, 95% 에탄올 50㎕ 와 혼합하여 얼음 위에 10분간 방치한 뒤 11000rpm 에서 20분간 원심분리하고 침전물을 70% 에탄올 250㎕로 세척한 후 진공건조 시킨 뒤 6㎕ 주입 완충액(loading buffer) (탈이온화 포름아미드 5㎕, 50mg/ml 블루 덱스트란 1㎕를 함유하는 25mM EDTA(pH 8.0)에 용해하였다. 주입 직전에 90℃에서 2분간 변성시킨후 1.5㎕ 씩을 4% 폴리아크릴아미드 시퀀싱 겔에서 3000V로 전기영동하고 ABI PRISMTM377 DNA Sequencer로 염기서열 결과를 판독하였다.Sequence determination of the amplified DNA was performed using ABI PRISM TM Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer), 8 μl Terminator Ready Reaction Mix per 20 μl of reaction solution, 3.2 μl of 1 μM primer and 30 100 ng of A template was added and mineral oil was added and amplified in 25 cycles by a thermal cycler. Cycles used for amplification were 96 ° C 30 seconds, 50 ° C 15 seconds, 60 ° C 4 minutes, and the first cycle was 96 ° C 5 minutes. After completion of the amplification, the reaction solution was mixed with 2 µl of 3M sodium acetate (pH 4.6) and 50 µl of 95% ethanol, left on ice for 10 minutes, centrifuged at 11000 rpm for 20 minutes, and the precipitate was washed with 250 µl of 70% ethanol. After vacuum drying, the solution was dissolved in 25 mM EDTA (pH 8.0) containing 6 µl of loading buffer (5 µl of deionized formamide, 1 µl of 50 mg / ml blue dextran). 1.5 μl each was electrophoresed at 3000 V on a 4% polyacrylamide sequencing gel, and the sequencing results were read with an ABI PRISM ™ 377 DNA Sequencer.
3. 결과의 분석3. Analysis of the results
(1) 대상군의 특성(1) Characteristics of the target group
대상군은 1996년 8월초부터 1997년 10월말까지 국군수도병원및 고려대학교 임상병리과학 교실로 의뢰된 말라리아 환자 25명의 검체로서 지역별 분포는 파주 지역이 12명(48 %), 연천 지역이 9명 (36 %)이었다(표 1). 성별로는 남자환자가 25명중 24명(96%), 여자환자는 25명 중 1명 (4 %)이었다 (표 1).The subjects were 25 patients with malaria who were referred to the National Military Capital Hospital and Korea University Clinical Pathology Department from the beginning of August 1996 to the end of October 1997. The distribution of each region was 12 in Paju (48%) and 9 in Yeoncheon. (36%) (Table 1). By gender, 24 of 25 patients (96%) and 1 of 25 patients (4%) were women (Table 1).
(2) 환자의 직업은 현역 군인이 20명(80%)으로 가장 많았고 군 제대자가 3명(12%), 그리고 운전기사와 학생은 각각 1명이 존재하였다. 연령은 주로 20대로서 평균 연령은 23세(12-45세)였다.(2) The occupation of the patients was the highest number of active soldiers (20 people (80%), 3 soldiers (12%), one driver and one student each). The age was mainly in their twenties, with an average age of 23 years (12-45 years).
(3) 검사시기는 96년이 23명 97년이 2명이었으며 대상 검체는 6월이 8예(32%)로 가장 많았고 다음이 9월 (28%), 10월이 4명 (12%)순이었다.(3) The test period was 23 in 96 years and 2 in 97 years. The most common specimens were 8 cases (32%) in June, followed by September (28%) and 4 in October (12%). It was net.
(4) 확진된 환자 24명은 모두 병력 조사상 외국 여행을 한 적이 없었으며 수혈받은 경력도 없는 국내 거주자로 환자는 국내 발생 삼일열 말라리아(Plasmodium vivax)이었으며 원충의 농도는 최저 23/㎕ 농도에서 최고 15,330/㎕의 농도로 평균 2,040/㎕였다.(4) All 24 confirmed patients had never traveled abroad and had no history of blood transfusion. The patient was domestically produced Plasmodium vivax, and the concentration of protozoa was the highest at the lowest 23 / μl concentration. The average was 2,040 / μl at a concentration of 15,330 / μl.
2. 삼일열 말라리아 분열소체 표면 단백의 중합 효소 연쇄반응 결과2. Results of Polymerase Chain Reaction of Surface Protein of Tritiated Malaria Cleavage
전체 25명의 환자 중 19예 (76%)가 서컴스포로조이트 표면 단백(CSP), 분열소체 표면 단백(MSP) 및 더피 혈액형 부착 단백(DBP)을 이용한 중합효소 연쇄반응에서 양성의 소견을 보였는데, MSP의 경우 약 300bp근처에서 (도 1), 그리고 CSP의 경우 600-700bp에서 보이는 DNA 분획을 확인하였다(도 2). 도 1에서 레인 1은 분자량 마커, 레인 2는 약한 양성, 레인 3과 4는 음성, 레인 5는 양성, 레인 6은 음성, 레인 7은 강한 양성, 레인 8은 음성, 레인 9는 양성, 레인 10은 음성, 그리고 레인 11은 양성 시료를 각각 나타낸다. 도 2에서 레인 1은 분자량 마커, 레인 2와 3은 강한 양성, 레인 4 내지 레인 7은 음성을 나타낸다.Nineteen (76%) of 25 patients showed positive results in polymerase chain reaction using circus spheroid surface protein (CSP), fissile surface protein (MSP) and Duffy blood group adhesion protein (DBP). In the case of MSP, DNA fractions were observed around 300bp (Figure 1) and CSP at 600-700bp (Figure 2). In Figure 1 lane 1 is a molecular weight marker, lane 2 is weak positive, lanes 3 and 4 negative, lane 5 positive, lane 6 negative, lane 7 strong positive, lane 8 negative, lane 9 positive, lane 10 Is negative and lane 11 represents a positive sample, respectively. In FIG. 2, lane 1 represents a molecular weight marker, lanes 2 and 3 are strong positive, and lanes 4 to 7 are negative.
말라리아 중합효소 반응 양성예의 말초혈액상 원충의 농도는 최저 23/㎕에서 최고 15,330/㎕이었으며 평균 2,630/㎕의 소견을 보였다. 말초도말 소견에서 양성이나 말라리아 중합 효소반응에 음성인 예에서는 최저 56/㎕에서 최고 1,320/㎕의 넓은 분포를 보였으나 평균 원충농도는 양성예에 비해 현저하게 낮았다.Peripheral blood protozoa concentrations of positive malaria polymerase reactions ranged from 23 / μl to 15,330 / μl and averaged 2,630 / μl. In peripheral smears, the positive or malaria polymerase reaction showed a wide distribution ranging from 56 / μl to 1,320 / μl, but the mean protozoa concentration was significantly lower than that of positive cases.
3. 한국의 재발생 삼일열 말라리아의 분열소체 표면 단백의 염기서열 및 아미노산 서열3. Nucleotide Sequences and Amino Acid Sequences of the Cleavage Surface Proteins of Reoccurring Triplet Malaria in Korea
삼일열 말라리아의 분열소체 표면 단백의 염기서열 및 그에 의해 코딩되는 표면 단백의 아미노산 서열을 각각 서열 번호 1 및 2에 나타내었다. 그외 참고로 서컴스포로조이트 표면 단백의 염기서열 및 아미노산 서열을 각각 서열 번호 3과 4로, 그리고 더피 혈액형 부착 단백의 염기서열 및 아미노산 서열을 각각 서열 번호 5와 6으로 표시하였다.The nucleotide sequence of the cleavage surface protein of trigeminal malaria and the amino acid sequence of the surface protein encoded by it are shown in SEQ ID NOs: 1 and 2, respectively. For reference, the nucleotide sequence and amino acid sequence of the circus sporozoite surface protein were shown as SEQ ID NOs: 3 and 4, respectively, and the nucleotide sequence and amino acid sequence of the Duffy blood type attachment protein were shown as SEQ ID NOs: 5 and 6, respectively.
본 기술의 의미를 분석해 보면 한국의 삼일열 말라리아의 독특한 유전자는 외국의 삼일열 말라리아 유전자와 달라서 이 유전자를 기초로 진단 시약을 제조하거나 백신을 제조하는 경우 효과가 외국에서 들여오는 시약에 비하여 높은 예민도와 효과를 보일 수 있어 말라리아 예방에 도움이 된다.The analysis of the meaning of this technology shows that the unique gene of Korea's triplet malaria is different from that of foreign triplet malaria, so that the production of diagnostic reagents or vaccines based on these genes has a higher sensitivity than foreign reagents. It can be effective in preventing malaria.
참고문헌references
1. Bruce-Chwatt L. J. (1987) Malaria and its control. Present situation and future prospects. Annual Review of Public Health 8: 75-110Bruce-Chwatt L. J. (1987) Malaria and its control. Present situation and future prospects. Annual Review of Public Health 8: 75-110
2. Gilles H.M., Warrel, D.A.. Bruce-Chwatt's essential malariology. 3rd ed. London, Edward Arnold, 1993, pp5-6Gilles H.M., Warrel, D. A. Bruce-Chwatt's essential malariology. 3rd ed. London, Edward Arnold, 1993, pp 5-6
3. Chadee DD, Maitre AL, Tilluckdharry CC. An outbreak of Plasmodium vivax malaria in Trinidad, W.I.. Ann Trop Med Parasit 86; 583-590, 1992Chadee DD, Maitre AL, Tilluckdharry CC. An outbreak of Plasmodium vivax malaria in Trinidad, W.I .. Ann Trop Med Parasit 86; 583-590, 1992
4.Paik YH, Ree HI, Shim JC: Malaria in Korea. Kyung Hee Univ Med J 12:17-31, 1987Paik YH, Ree HI, Shim JC: Malaria in Korea. Kyung Hee Univ Med J 12: 17-31, 1987
5.Paik YH, Ree HI, Shim JC: Malaria in Korea. Jpn J Exp Med 58: 55-60 19885.Paik YH, Ree HI, Shim JC: Malaria in Korea. Jpn J Exp Med 58: 55-60 1988
6.Pull JH. Malaria Surveillance Methods, Their Uses and Limitations. American J of Tropical Medicine and Hygiene 21(5): 651-657 19726.Pull JH. Malaria Surveillance Methods, Their Uses and Limitations. American J of Tropical Medicine and Hygiene 21 (5): 651-657 1972
7. 채인호, 임건일, 윤성노, 오원일, 김선주, 채종일: 외국여행 경력이 없는 남자환자에서 발병한 삼일열 말라리아 1예. 기생충학잡지, 32(3): 195-200, 19947. Chae In-ho, Lim Gun-il, Sung-no Yoon, Won-il Oh, Sun-joo Kim, Jong-il Chae: A case of malaria caused by three days of fever in a male patient who has not traveled abroad. Parasitology Magazine, 32 (3): 195-200, 1994
8. 서재홍, 김신곤, 정희진, 김우주, 김민자, 박승철. 1994년 한국에서 발생한 Plasmodium vivax에 의한 malaria 1예. 감염 1995;27:83-868. Jae-Hong Seo, Shin-Kon Kim, Hee-Jin Jung, Kim Woo-Ju, Kim Min-Ja, Park Seung-Chul. A Case of Malaria Caused by Plasmodium vivax in Korea in 1994. Infection 1995; 27: 83-86
9. 임채승, 김영기, 이갑노, 김광희, 김홍석, 임현우, 김병수, 김준석. 한국에서 재발된 토착형 말라리아의 혈액학적 소견. 대한임상병리학회지, 1996; 16(6): 836-8439. Chae-seung Lim, Kim Young-ki, Lee Kap-no, Kim Kwang-hee, Kim Hong-seok, Lim Hyun-woo, Kim Byeong-su, Kim Jun-suk. Hematological Findings of Indigenous Malaria Recurring in Korea. Korean Journal of Clinical Pathology, 1996; 16 (6): 836-843
10. 임현우, 서지영, 안영수, 오상용, 김동립, 임채승. 1995년 국군병사에서 발생한 국내감염 말라리아 환자 87명에 대한 역학적 임상적 분석. 감염학회지 1996;28(3):219-22410. Hyun Woo Lim, Ji Young Suh, Young Soo Ahn, Sang Yong Oh, Dong Rip Kim, Chae Seung Lim. Epidemiologic and Clinical Analysis of 87 Infected Malaria Patients in 1995 Military Armed Forces. Korean Journal of Infectious Disease 1996; 28 (3): 219-224
11.김광희, 임채승. 1995년에 발병한 토착형 말라리아 26예에 대한 임상적 고찰. 대한 내과학회지 52:2:577-583,199711.Kim Kwang-hee and Lim Chae-seung. Clinical Study of 26 Indigenous Malaria in 1995. Korean Journal of Internal Medicine 52: 2: 577-583,1997
12.임채승,김영기,이갑노,김대성,김순덕,염용태. Acridine Orange염색법을 이용한 말라리아의 진단. 감염 29:2:119-124, 199712. Lim Chae-seung, Kim Young-ki, Lee Kap-no, Kim Dae-sung, Kim Soon-deok, Yeom Yong-tae. Diagnosis of Malaria by Acridine Orange Staining. Infection 29: 2: 119-124, 1997
13. 김대성,김순덕,염용태,임채승,이갑노,박미숙,윤배중.국내발생 말라리아에 대한 감시체계 구축.한국역학회지 1997.19:(2).180-18913. Kim, Dae-Sung, Kim, Soon-Duck, Yong-Tae, Yim, Chae-Seung, Lee, Gap-No, Park, Mi-Sook, Yoon, Bae-Jung, Development of Surveillance System for Malaria in Korea. Journal of the Korean Society for Epidemiology 1997.19: (2) .180-189
14.임채승,마경란,김영기,이갑노,김광희,김대성,Makler MT.파열된 분열체와 방출된 분열소체 만 보이는 삼일열 말라리아 1예.감염.1997.29:(6).509-51214. Lim Chae-seung, Ma Kyung-ran, Kim Young-ki, Lee Kap-no, Kim Kwang-hee, Kim Dae-sung, Makler MT. A case of febrile malaria with only visible ruptured and released fissile bodies.Infection. 1997.29: (6) .509-512
15.임채승,마경란,김영기,이갑노,김광희,김민자,고원규,김대성.한국에서 재발생한 삼일열 말라리앙 81예의 치료 성적.감염.1997.29:(5).413-41615. Lim Chae-seung, Ma Kyung-ran, Kim Young-ki, Lee Kap-no, Kim Kwang-hee, Kim Min-ja, Ko Won-kyu, Kim Dae-sung.
16.임채승,김영기,이갑노,염용태,김순덕,김대성,황유성,오홍범,김두성.군장병의 헌혈을 통한 말라리아 전파의 위험성에 대한 조사.감염.1997,29:(2),113-117Kim Chae-seung, Kim Young-ki, Lee Kap-no, Yeom Yong-tae, Kim Soon-deok, Kim Dae-sung, Hwang Yu-sung, Oh Hong-bum, Kim Doo-sung.Investigation of the risk of malaria transmission through donation of military soldiers.
17.임채승,김영기,이갑노,이형우,이원자,이종수,조남선,김대성. 말라리아 호발지역에서 채혈된 주민과 군헌혈자에서 말라리아 검사성적. 대한수혈학회지.1997,8:(2),291-29917. Chae-seung Lim, Kim Young-ki, Lee Kap-no, Lee Hyung-woo, Lee Won-ja, Lee Jong-soo, Cho Nam-sun, Kim Dae-sung. Malaria test scores in residents and military donors collected from malaria-provoked areas. Korean Journal of Blood Transfusion. 1997,8: (2), 291-299
18.Sinnis P, Sim BK: Cell invasion by the vertebrate stages of Plasmodium. Trend. in Microbiology 5:2:52-58, 199718. Sinnis P, Sim BK: Cell invasion by the vertebrate stages of Plasmodium. Trend. in Microbiology 5: 2: 52-58, 1997
19.David PH, Hudson DE, Hadley TJ, Klotz FW, Miller LH: Immunization of monkeys with a 140 kilodalton merozoite surface protein of Plasmodium knowlesi malaria: apperence of alternate form of this protein. J of Immunology 1985:134:4146-415219.David PH, Hudson DE, Hadley TJ, Klotz FW, Miller LH: Immunization of monkeys with a 140 kilodalton merozoite surface protein of Plasmodium knowlesi malaria: apperence of alternate form of this protein. J of Immunology 1985: 134: 4146-4152
20. Sedegah M, Hedstrom R, Hobart P, Hoffmann SI. Protection against malari aby immunization with plasmid DNA encoding circumsporozoite protein, Proc Natl Acad Sci U S A 1994:91:9866-7020. Sedegah M, Hedstrom R, Hobart P, Hoffmann SI. Protection against malari aby immunization with plasmid DNA encoding circumsporozoite protein, Proc Natl Acad Sci U S A 1994: 91: 9866-70
21.Fang X, Kaslow DC, Adams JH, MIller LH. Cloning of the Plasmodium vivax Duffy receptor.Mol. Biochem Parasitol. 44,125-132, 199121. Fang X, Kaslow DC, Adams JH, MIller LH. Cloning of the Plasmodium vivax Duffy receptor. Mol. Biochem Parasitol. 44,125-132, 1991
22.Holder AA, Freedman RR. Biosynthesisi and processing of a Plasmodium falciparum antigen recognized by immune serum and a monoclonal antibody. Journal of experimental medicine 1982, 156:1528-153822.Holder AA, Freedman RR. Biosynthesisi and processing of a Plasmodium falciparum antigen recognized by immune serum and a monoclonal antibody. Journal of experimental medicine 1982, 156: 1528-1538
23.Udagama PV, David PH, Peiris JS, Aryavatne YG, Perera KL, Menis KN. Demonstration of antigenic polymorphism in Plasmodium vivax malaria with a panel of 30 monoclonal antibodies. Infection and immunity 1987, 55:2604-261123.Udagama PV, David PH, Peiris JS, Aryavatne YG, Perera KL, Menis KN. Demonstration of antigenic polymorphism in Plasmodium vivax malaria with a panel of 30 monoclonal antibodies. Infection and immunity 1987, 55: 2604-2611
24. Del Portillo HA, Longacre S. Khouri E, David PH: Primary structure of the merozoite surface antigen 1 of plasmodium vivax reveals sequence conserved between different plasmodium species. Pro National Academy science 1991, 88,4030-415224. Del Portillo HA, Longacre S. Khouri E, David PH: Primary structure of the merozoite surface antigen 1 of plasmodium vivax reveals sequence conserved between different plasmodium species. Pro National Academy science 1991, 88,4030-4152
25. Gibson HL, Tucker JE, Kaslow DC, Krettli AU, Collins WE, Kiefer MC, Bathurst IA, Barr PJ. Structure and expression of the gene for Pv200, amajor blood stage surface antigen of Plasmodium vivax. molecular and biochemical Parasitology 1992,50:325-33425.Gibson HL, Tucker JE, Kaslow DC, Krettli AU, Collins WE, Kiefer MC, Bathurst IA, Barr PJ. Structure and expression of the gene for Pv200, amajor blood stage surface antigen of Plasmodium vivax. molecular and biochemical Parasitology 1992, 50: 325-334
26. Prewansa S, Snewin VA, Khouri E, Mendis KN, David PH. Plasmodium vivax: Recombination between potential alleic types of the merozoite surface protein MSP1 in parasite isolate from patients. Experimental parasitology 1993:76:192-19926. Prewansa S, Snewin VA, Khouri E, Mendis KN, David PH. Plasmodium vivax: Recombination between potential alleic types of the merozoite surface protein MSP1 in parasite isolate from patients. Experimental parasitology 1993: 76: 192-199
27. 이준상, 주경환 등. 임상기생충학. 고려의학 1993 쪽77-97, 쪽269-276, 쪽313-31727. Lee Jun-sang, Ju Kyung-hwan and others. Clinical Parasitology. Korea Medical Sciences 1993 pp. 77-97, pp. 269-276, pp. 313-317
28.서병설: 최신임상기생충학. 일조각 83-98, 198528. Seo Byung-Sul: Modern Clinical Nephrology. Piece 83-98, 1985
29.백영한, Tsai FC: 한국의 3일열의 역학적 고찰. 최신의학 1963;6(2):189-19529. Baek Young-han, Tsai FC: An epidemiological study of the three-day fever in Korea. Advanced Medicine 1963; 6 (2): 189-195
30.Henry JB. Clinical diagnosis and management by laboratory method, 18th ed, WB Saunders Company, Philadelphia PA, 1991:1168-117230.Henry JB. Clinical diagnosis and management by laboratory method, 18th ed, WB Saunders Company, Philadelphia PA, 1991: 1168-1172
31.World Health Organization (1974) Serological testing in malaria (Memorandum). Bulletin of the World Health Organization 50 : 527-3531.World Health Organization (1974) Serological testing in malaria (Memorandum). Bulletin of the World Health Organization 50: 527-35
32. Kevin CK, Arthur EB,Laura M, Webster HK.Detection of Plasmodium vivax by polymerase chain reaction in a field study. J Inf Dis 168:1322-1326,199332. Kevin CK, Arthur EB, Laura M, Webster HK.Detection of Plasmodium vivax by polymerase chain reaction in a field study. J Inf Dis 168: 1322-1326,1993
33.Gorden DM, Cosgriff TM, Schneider I, Wassermanm GF, Majarian WR, Holingdale MR, Chulay JD. Safety and immunogenecity of a Plasmodium vivax sporozoite vaccine. Am J Trop Med Hyg, 42:525-31,199033. Gordon DM, Cosgriff ™, Schneider I, Wassermanm GF, Majarian WR, Holingdale MR, Chulay JD. Safety and immunogenecity of a Plasmodium vivax sporozoite vaccine. Am J Trop Med Hyg, 42: 525-31, 1990
34.Plebanski M, Aidoo M, Whittle HC, Hill AV.Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of Plasmodium falciparum in West Africa. J Immunol 1997 15;158(6):2849-285534. Plebanski M, Aidoo M, Whittle HC, Hill AV. Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of Plasmodium falciparum in West Africa. J Immunol 1997 15; 158 (6): 2849-2855
35.Robson KJ, Dolo A, Hackford IR, Doumbo O, Richards MB, Keita MM,Sidibe T, Bosman A, Modiano D, Crisanti A.Natural polymorphism in the thrombospondin-related adhesive protein of Plasmodium falciparum. Am J Trop Med Hyg 1998 Jan;58(1):81-8935. Robson KJ, Dolo A, Hackford IR, Doumbo O, Richards MB, Keita MM, Siidi T, Bosman A, Modiano D, Crisanti A. Natural polymorphism in the thrombospondin-related adhesive protein of Plasmodium falciparum. Am J Trop Med Hyg 1998 Jan; 58 (1): 81-89
36.Bottius E, BenMohamed L, Brahimi K, Gras H, Lepers JP, Raharimalala L,Aikawa M, Meis J, Slierendregt B, Tartar A, Thomas A, Druilhe P.A novel Plasmodium falciparum sporozoite and liver stage antigen (SALSA) defines major B, Thelper, and CTL epitopes.J Immunol 1996 Apr 15;156(8):2874-288436.Bottius E, BenMohamed L, Brahimi K, Gras H, Lepers JP, Raharimalala L, Aikawa M, Meis J, Slierendregt B, Tartar A, Thomas A, Druilhe PA novel Plasmodium falciparum sporozoite and liver stage antigen (SALSA) defines major B, Thelper, and CTL epitopes. J Immunol 1996 Apr 15; 156 (8): 2874-2884
37.Kolakovich KA, Ssengoba A, Wojcik K, Tsuboi T, al-Yaman F, Alpers M,Adams JH. Plasmodium vivax: favored gene frequencies of the merozoite surface protein-1 and the multiplicity of infection in a malaria endemic region.Exp Parasitol 1996 Jun;83(1):11-1937. Kolakovich KA, Ssengoba A, Wojcik K, Tsuboi T, al-Yaman F, Alpers M, Adams JH. Plasmodium vivax: favored gene frequencies of the merozoite surface protein-1 and the multiplicity of infection in a malaria endemic region.Exp Parasitol 1996 Jun; 83 (1): 11-19
38. Putaporntip,C., Jongwutiwes,S., Tanabe,K. and Thaithong,S.Interallelic recombination in the merozoite surface protein 1(MSP-1) gene of Plasmodium vivax from Thai isolates. Mol. Biochem. Parasitol. 84 (1), 49-56 (1997)38. Putaporntip, C., Jongwutiwes, S., Tanabe, K. and Thaithong, S. Interallelic recombination in the merozoite surface protein 1 (MSP-1) gene of Plasmodium vivax from Thai isolates. Mol. Biochem. Parasitol. 84 (1), 49-56 (1997)
39. Putaporntip,C., Jongwutiwes,S., Tanabe,K. and Thaithong,S. Interallelic recombination in the merozoite surface protein 1 (MSP-1) gene of Plasmodium vivax from Thai isolates. Mol. Biochem. Parasitol. 84 (1), 49-56 (1997)39. Putaporntip, C., Jongwutiwes, S., Tanabe, K. and Thaithong, S. Interallelic recombination in the merozoite surface protein 1 (MSP-1) gene of Plasmodium vivax from Thai isolates. Mol. Biochem. Parasitol. 84 (1), 49-56 (1997)
서열목록Sequence Listing
(1) (i) 출원인 : 임 채 승(1) (i) Applicant: Lim Chae Seung
(ii) 발명의 명칭 : 말라리아의 검출방법(ii) Name of the invention: Method of detecting malaria
(iii) 서열의 수: 12(iii) number of sequences: 12
(2) 서열번호1에 대한 정보(2) Information about SEQ ID NO: 1
(i) 서열의 특징:(i) sequence characteristics:
(A) 길이: 306 base pairs(A) Length: 306 base pairs
(B) 타입: 핵산(B) Type: nucleic acid
(C) 쇄의 수 : 1본쇄(C) Number of chains: 1 chain
(D) 토폴로지 : 선형(D) topology: linear
(ii) 분자의 타입: DNA (genomic)(ii) Type of molecule: DNA (genomic)
(vi) 기원:(vi) origin:
(A) 생물명: Plasmodium vivax(A) Biometric: Plasmodium vivax
(ix) 서열의 특징:(ix) sequence characteristics:
(A) 특징을 나타내는 기호 : CDS(A) Characteristic symbols: CDS
(B) 존재위치:1..306(B) Presence location: 1..306
(xi) 서열의 기재방법: SEQ ID NO: 1:(xi) a method for describing a sequence: SEQ ID NO: 1:
GCA GAA GAC GCA GGA GGA AAC GCA GGA GGA AAC GCA GGA GGA CAG GGA 48GCA GAA GAC GCA GGA GGA AAC GCA GGA GGA AAC GCA GGA GGA CAG GGA 48
Ala Glu Asp Ala Gly Gly Asn Ala Gly Gly Asn Ala Gly Gly Gln GlyAla Glu Asp Ala Gly Gly Asn Ala Gly Gly Asn Ala Gly Gly Gln Gly
1 5 10 151 5 10 15
CAA AAT AAT GAA GGT GCG AAT GCC CCA AAT GAA AAG TCT GTG AAA GAA 96CAA AAT AAT GAA GGT GCG AAT GCC CCA AAT GAA AAG TCT GTG AAA GAA 96
Gln Asn Asn Glu Gly Ala Asn Ala Pro Asn Glu Lys Ser Val Lys GluGln Asn Asn Glu Gly Ala Asn Ala Pro Asn Glu Lys Ser Val Lys Glu
20 25 3020 25 30
TAC CTA GAT AAA GTT AGA GCT ACC GTT GGC ACC GAA TGG ACT CCA TGC 144TAC CTA GAT AAA GTT AGA GCT ACC GTT GGC ACC GAA TGG ACT CCA TGC 144
Tyr Leu Asp Lys Val Arg Ala Thr Val Gly Thr Glu Trp Thr Pro CysTyr Leu Asp Lys Val Arg Ala Thr Val Gly Thr Glu Trp Thr Pro Cys
35 40 4535 40 45
AGT GTA ACC TGT GGA GTG GGT GTA AGA GTC AGA AGA AGA GTT AAT GCA 192AGT GTA ACC TGT GGA GTG GGT GTA AGA GTC AGA AGA AGA GTT AAT GCA 192
Ser Val Thr Cys Gly Val Gly Val Arg Val Arg Arg Arg Val Asn AlaSer Val Thr Cys Gly Val Gly Val Arg Val Arg Arg Arg Val Asn Ala
50 55 6050 55 60
GCT AAC AAA AAA CCA GAG GAT CTT ACT TTG AAT GAC CTT GAG ACT GAT 240GCT AAC AAA AAA CCA GAG GAT CTT ACT TTG AAT GAC CTT GAG ACT GAT 240
Ala Asn Lys Lys Pro Glu Asp Leu Thr Leu Asn Asp Leu Glu Thr AspAla Asn Lys Lys Pro Glu Asp Leu Thr Leu Asn Asp Leu Glu Thr Asp
65 70 75 8065 70 75 80
GTT TGT ACA ATG GAT AAG TGT GCT GGC ATA TTT AAC GTT GTG AGT AAT 288GTT TGT ACA ATG GAT AAG TGT GCT GGC ATA TTT AAC GTT GTG AGT AAT 288
Val Cys Thr Met Asp Lys Cys Ala Gly Ile Phe Asn Val Val Ser AsnVal Cys Thr Met Asp Lys Cys Ala Gly Ile Phe Asn Val Val Ser Asn
85 90 9585 90 95
TCA TTA GGG CTA GTC ATA 306TCA TTA GGG CTA GTC ATA 306
Ser Leu Gly Leu Val IleSer Leu Gly Leu Val Ile
100100
(2) 서열번호2에 대한 정보2:(2) information on SEQ ID NO: 2:
(i) 서열의 특징:(i) sequence characteristics:
(A) 길이: 102 amino acids(A) Length: 102 amino acids
(B) 타입: 아미노산(B) type: amino acid
(D) 토폴로지 : 선형(D) topology: linear
(ii) 분자의 타입: 단백질(ii) Type of molecule: protein
(xi) 서열의 기재방법: SEQ ID NO: 2:(xi) a method for describing a sequence: SEQ ID NO: 2:
Ala Glu Asp Ala Gly Gly Asn Ala Gly Gly Asn Ala Gly Gly Gln GlyAla Glu Asp Ala Gly Gly Asn Ala Gly Gly Asn Ala Gly Gly Gln Gly
1 5 10 151 5 10 15
Gln Asn Asn Glu Gly Ala Asn Ala Pro Asn Glu Lys Ser Val Lys GluGln Asn Asn Glu Gly Ala Asn Ala Pro Asn Glu Lys Ser Val Lys Glu
20 25 3020 25 30
Tyr Leu Asp Lys Val Arg Ala Thr Val Gly Thr Glu Trp Thr Pro CysTyr Leu Asp Lys Val Arg Ala Thr Val Gly Thr Glu Trp Thr Pro Cys
35 40 4535 40 45
Ser Val Thr Cys Gly Val Gly Val Arg Val Arg Arg Arg Val Asn AlaSer Val Thr Cys Gly Val Gly Val Arg Val Arg Arg Arg Val Asn Ala
50 55 6050 55 60
Ala Asn Lys Lys Pro Glu Asp Leu Thr Leu Asn Asp Leu Glu Thr AspAla Asn Lys Lys Pro Glu Asp Leu Thr Leu Asn Asp Leu Glu Thr Asp
65 70 75 8065 70 75 80
Val Cys Thr Met Asp Lys Cys Ala Gly Ile Phe Asn Val Val Ser AsnVal Cys Thr Met Asp Lys Cys Ala Gly Ile Phe Asn Val Val Ser Asn
85 90 9585 90 95
Ser Leu Gly Leu Val IleSer Leu Gly Leu Val Ile
100100
(2) 서열번호3에 대한 정보:(2) Information about SEQ ID NO:
(i) 서열의 특징:(i) sequence characteristics:
(A) 길이: 681 base pairs(A) Length: 681 base pairs
(B) 타입: 핵산(B) Type: nucleic acid
(C) 쇄의 수 : 1본쇄(C) Number of chains: 1 chain
(D) 토폴로지 : 선형(D) topology: linear
(ii) 분자의 타입: DNA (genomic)(ii) Type of molecule: DNA (genomic)
(vi) 기원:(vi) origin:
(A) 생물명: Plasmodium vivax(A) Biometric: Plasmodium vivax
(ix) 서열의 특징:(ix) sequence characteristics:
(A) 특징을 나타내는 기호 : CDS(A) Characteristic symbols: CDS
(B) 존재위치:1..681(B) Presence location: 1..681
(xi) 서열의 기재방법: SEQ ID NO: 3:(xi) a method for describing a sequence: SEQ ID NO: 3:
CAC AAT GTA GAT CTG TCC AAG GCC ACA AAT ATA AAT GGA GCA AAC TTC 48CAC AAT GTA GAT CTG TCC AAG GCC ACA AAT ATA AAT GGA GCA AAC TTC 48
His Asn Val Asp Leu Ser Lys Ala Thr Asn Ile Asn Gly Ala Asn PheHis Asn Val Asp Leu Ser Lys Ala Thr Asn Ile Asn Gly Ala Asn Phe
105 110 115105 110 115
AAT AAT GTA GAC GCC AGT TCA CTT GGC GCG GCA CAC GTA GGA CAA AGT 96AAT AAT GTA GAC GCC AGT TCA CTT GGC GCG GCA CAC GTA GGA CAA AGT 96
Asn Asn Val Asp Ala Ser Ser Leu Gly Ala Ala His Val Gly Gln SerAsn Asn Val Asp Ala Ser Ser Leu Gly Ala Ala His Val Gly Gln Ser
120 125 130120 125 130
GCT AGC CGA GGC AGA GGA CTT GGT GAG AAC CCA GAT GAC GAG GAA GGA 144GCT AGC CGA GGC AGA GGA CTT GGT GAG AAC CCA GAT GAC GAG GAA GGA 144
Ala Ser Arg Gly Arg Gly Leu Gly Glu Asn Pro Asp Asp Glu Glu GlyAla Ser Arg Gly Arg Gly Leu Gly Glu Asn Pro Asp Asp Glu Glu Gly
135 140 145 150135 140 145 150
GAT GCT AAA AAA AAA AAG GGG GGA AAG AAA GCA GAA CCA AAA AAT CCA 192GAT GCT AAA AAA AAA AAG GGG GGA AAG AAA GCA GAA CCA AAA AAT CCA 192
Asp Ala Lys Lys Lys Lys Gly Gly Lys Lys Ala Glu Pro Lys Asn ProAsp Ala Lys Lys Lys Lys Gly Gly Lys Lys Ala Glu Pro Lys Asn Pro
155 160 165155 160 165
CGT GAA AAT AAG CTG AAA CAA CCA GGA GAC AGA GCA GGT GGA CAG CCA 240CGT GAA AAT AAG CTG AAA CAA CCA GGA GAC AGA GCA GGT GGA CAG CCA 240
Arg Glu Asn Lys Leu Lys Gln Pro Gly Asp Arg Ala Gly Gly Gln ProArg Glu Asn Lys Leu Lys Gln Pro Gly Asp Arg Ala Gly Gly Gln Pro
170 175 180170 175 180
GCA GGA AAT GGT GCA GGT GGA CAG CCA GCA GGA AAT GGT GCA GGT GGA 288GCA GGA AAT GGT GCA GGT GGA CAG CCA GCA GGA AAT GGT GCA GGT GGA 288
Ala Gly Asn Gly Ala Gly Gly Gln Pro Ala Gly Asn Gly Ala Gly GlyAla Gly Asn Gly Ala Gly Gly Gln Pro Ala Gly Asn Gly Ala Gly Gly
185 190 195185 190 195
CAG GCA GCA GGA AAT GGT GCA GGT GGA CAG GCA GCA GGA GGA AAT GCG 336CAG GCA GCA GGA AAT GGT GCA GGT GGA CAG GCA GCA GGA GGA AAT GCG 336
Gln Ala Ala Gly Asn Gly Ala Gly Gly Gln Ala Ala Gly Gly Asn AlaGln Ala Ala Gly Asn Gly Ala Gly Gly Gln Ala Ala Gly Gly Asn Ala
200 205 210200 205 210
GCA AAC AAG AAG GCA GAA GAC GCA GGA GGA AAC GCA GGA GGA AAC GCA 384GCA AAC AAG AAG GCA GAA GAC GCA GGA GGA AAC GCA GGA GGA AAC GCA 384
Ala Asn Lys Lys Ala Glu Asp Ala Gly Gly Asn Ala Gly Gly Asn AlaAla Asn Lys Lys Ala Glu Asp Ala Gly Gly Asn Ala Gly Gly Asn Ala
215 220 225 230215 220 225 230
GGA GGA CAG GGA CAA AAT AAT GAA GGT GCG AAT GCC CCA AAT GAA AAG 432GGA GGA CAG GGA CAA AAT AAT GAA GGT GCG AAT GCC CCA AAT GAA AAG 432
Gly Gly Gln Gly Gln Asn Asn Glu Gly Ala Asn Ala Pro Asn Glu LysGly Gly Gln Gly Gln Asn Asn Glu Gly Ala Asn Ala Pro Asn Glu Lys
235 240 245235 240 245
TCT GTG AAA GAA TAC CTA GAT AAA GTT AGA GCT ACC GTT GGC ACC GAA 480TCT GTG AAA GAA TAC CTA GAT AAA GTT AGA GCT ACC GTT GGC ACC GAA 480
Ser Val Lys Glu Tyr Leu Asp Lys Val Arg Ala Thr Val Gly Thr GluSer Val Lys Glu Tyr Leu Asp Lys Val Arg Ala Thr Val Gly Thr Glu
250 255 260250 255 260
TGG ACT CCA TGC AGT GTA ACC TGT GGA GTG GGT GTA AGA GTC AGA AGA 528TGG ACT CCA TGC AGT GTA ACC TGT GGA GTG GGT GTA AGA GTC AGA AGA 528
Trp Thr Pro Cys Ser Val Thr Cys Gly Val Gly Val Arg Val Arg ArgTrp Thr Pro Cys Ser Val Thr Cys Gly Val Gly Val Arg Val Arg Arg
265 270 275265 270 275
AGA GTT AAT GCA GCT AAC AAA AAA CCA GAG GAT CTT ACT TTG AAT GAC 576AGA GTT AAT GCA GCT AAC AAA AAA CCA GAG GAT CTT ACT TTG AAT GAC 576
Arg Val Asn Ala Ala Asn Lys Lys Pro Glu Asp Leu Thr Leu Asn AspArg Val Asn Ala Ala Asn Lys Lys Pro Glu Asp Leu Thr Leu Asn Asp
280 285 290280 285 290
CTT GAG ACT GAT GTT TGT ACA ATG GAT AAG TGT GCT GGC ATA TTT AAC 624CTT GAG ACT GAT GTT TGT ACA ATG GAT AAG TGT GCT GGC ATA TTT AAC 624
Leu Glu Thr Asp Val Cys Thr Met Asp Lys Cys Ala Gly Ile Phe AsnLeu Glu Thr Asp Val Cys Thr Met Asp Lys Cys Ala Gly Ile Phe Asn
295 300 305 310295 300 305 310
GTT GTG AGT AAT TCA TTA GGG CTA GTC ATA TTG TTA TGC CTA GCA TTA 672GTT GTG AGT AAT TCA TTA GGG CTA GTC ATA TTG TTA TGC CTA GCA TTA 672
Val Val Ser Asn Ser Leu Gly Leu Val Ile Leu Leu Cys Leu Ala LeuVal Val Ser Asn Ser Leu Gly Leu Val Ile Leu Leu Cys Leu Ala Leu
315 320 325315 320 325
TTC AAT TAA 681TTC AAT TAA 681
Phe Asn *Phe Asn *
(2) 서열번호4에 대한 정보:(2) Information about SEQ ID NO:
(i) 서열의 특징:(i) sequence characteristics:
(A) 길이: 227 amino acids(A) Length: 227 amino acids
(B) 타입: 아미노산(B) type: amino acid
(D) 토폴로지 : 선형(D) topology: linear
(ii) 분자의 타입: 단백질(ii) Type of molecule: protein
(xi) 서열의 기재방법: SEQ ID NO: 4:(xi) Sequence description: SEQ ID NO: 4:
His Asn Val Asp Leu Ser Lys Ala Thr Asn Ile Asn Gly Ala Asn PheHis Asn Val Asp Leu Ser Lys Ala Thr Asn Ile Asn Gly Ala Asn Phe
1 5 10 151 5 10 15
Asn Asn Val Asp Ala Ser Ser Leu Gly Ala Ala His Val Gly Gln SerAsn Asn Val Asp Ala Ser Ser Leu Gly Ala Ala His Val Gly Gln Ser
20 25 3020 25 30
Ala Ser Arg Gly Arg Gly Leu Gly Glu Asn Pro Asp Asp Glu Glu GlyAla Ser Arg Gly Arg Gly Leu Gly Glu Asn Pro Asp Asp Glu Glu Gly
35 40 4535 40 45
Asp Ala Lys Lys Lys Lys Gly Gly Lys Lys Ala Glu Pro Lys Asn ProAsp Ala Lys Lys Lys Lys Gly Gly Lys Lys Ala Glu Pro Lys Asn Pro
50 55 6050 55 60
Arg Glu Asn Lys Leu Lys Gln Pro Gly Asp Arg Ala Gly Gly Gln ProArg Glu Asn Lys Leu Lys Gln Pro Gly Asp Arg Ala Gly Gly Gln Pro
65 70 75 8065 70 75 80
Ala Gly Asn Gly Ala Gly Gly Gln Pro Ala Gly Asn Gly Ala Gly GlyAla Gly Asn Gly Ala Gly Gly Gln Pro Ala Gly Asn Gly Ala Gly Gly
85 90 9585 90 95
Gln Ala Ala Gly Asn Gly Ala Gly Gly Gln Ala Ala Gly Gly Asn AlaGln Ala Ala Gly Asn Gly Ala Gly Gly Gln Ala Ala Gly Gly Asn Ala
100 105 110100 105 110
Ala Asn Lys Lys Ala Glu Asp Ala Gly Gly Asn Ala Gly Gly Asn AlaAla Asn Lys Lys Ala Glu Asp Ala Gly Gly Asn Ala Gly Gly Asn Ala
115 120 125115 120 125
Gly Gly Gln Gly Gln Asn Asn Glu Gly Ala Asn Ala Pro Asn Glu LysGly Gly Gln Gly Gln Asn Asn Glu Gly Ala Asn Ala Pro Asn Glu Lys
130 135 140130 135 140
Ser Val Lys Glu Tyr Leu Asp Lys Val Arg Ala Thr Val Gly Thr GluSer Val Lys Glu Tyr Leu Asp Lys Val Arg Ala Thr Val Gly Thr Glu
145 150 155 160145 150 155 160
Trp Thr Pro Cys Ser Val Thr Cys Gly Val Gly Val Arg Val Arg ArgTrp Thr Pro Cys Ser Val Thr Cys Gly Val Gly Val Arg Val Arg Arg
165 170 175165 170 175
Arg Val Asn Ala Ala Asn Lys Lys Pro Glu Asp Leu Thr Leu Asn AspArg Val Asn Ala Ala Asn Lys Lys Pro Glu Asp Leu Thr Leu Asn Asp
180 185 190180 185 190
Leu Glu Thr Asp Val Cys Thr Met Asp Lys Cys Ala Gly Ile Phe AsnLeu Glu Thr Asp Val Cys Thr Met Asp Lys Cys Ala Gly Ile Phe Asn
195 200 205195 200 205
Val Val Ser Asn Ser Leu Gly Leu Val Ile Leu Leu Cys Leu Ala LeuVal Val Ser Asn Ser Leu Gly Leu Val Ile Leu Leu Cys Leu Ala Leu
210 215 220210 215 220
Phe Asn *Phe Asn *
225225
(2) 서열번호5에 대한 정보:(2) Information about SEQ ID NO:
(i) 서열의 특징:(i) sequence characteristics:
(A) 길이: 739 base pairs(A) Length: 739 base pairs
(B) 타입: 핵산(B) Type: nucleic acid
(C) 쇄의 수 : 1본쇄(C) Number of chains: 1 chain
(D) 토폴로지 : 선형(D) topology: linear
(ii) 분자의 타입: DNA (genomic)(ii) Type of molecule: DNA (genomic)
(vi) 기원:(vi) origin:
(A) 생물명: Plasmodium vivax(A) Biometric: Plasmodium vivax
(ix) 서열의 특징:(ix) sequence characteristics:
(A) 특징을 나타내는 기호 : CDS(A) Characteristic symbols: CDS
(B) 존재위치:3..737(B) Presence Location: 3..737
(xi) 서열의 기재방법: SEQ ID NO: 5:(xi) a method for describing a sequence: SEQ ID NO: 5:
GT ATA CCC GAT CGA AGA TAT CAA TTA TGT ATG AAG GAA CTT ACG AAT 47GT ATA CCC GAT CGA AGA TAT CAA TTA TGT ATG AAG GAA CTT ACG AAT 47
Ile Pro Asp Arg Arg Tyr Gln Leu Cys Met Lys Glu Leu Thr AsnIle Pro Asp Arg Arg Tyr Gln Leu Cys Met Lys Glu Leu Thr Asn
230 235 240230 235 240
TTG GTA AAT AAT ACA GAC ACA AAT TTT CAT AGG GAT ATA ACA TTT CGA 95TTG GTA AAT AAT ACA GAC ACA AAT TTT CAT AGG GAT ATA ACA TTT CGA 95
Leu Val Asn Asn Thr Asp Thr Asn Phe His Arg Asp Ile Thr Phe ArgLeu Val Asn Asn Thr Asp Thr Asn Phe His Arg Asp Ile Thr Phe Arg
245 250 255245 250 255
AAA TTA TAT TTG AAA AGG AAA CTT ATT TAT GAT GCT GCA GTA GAG GGC 143AAA TTA TAT TTG AAA AGG AAA CTT ATT TAT GAT GCT GCA GTA GAG GGC 143
Lys Leu Tyr Leu Lys Arg Lys Leu Ile Tyr Asp Ala Ala Val Glu GlyLys Leu Tyr Leu Lys Arg Lys Leu Ile Tyr Asp Ala Ala Val Glu Gly
260 265 270260 265 270
GAT TTA TTA CTT AAG TTG AAT AAC TAC AGA TAT AAC AAA GAC TTT TGC 191GAT TTA TTA CTT AAG TTG AAT AAC TAC AGA TAT AAC AAA GAC TTT TGC 191
Asp Leu Leu Leu Lys Leu Asn Asn Tyr Arg Tyr Asn Lys Asp Phe CysAsp Leu Leu Leu Lys Leu Asn Asn Tyr Arg Tyr Asn Lys Asp Phe Cys
275 280 285 290275 280 285 290
AAG GAT ATA ACA TGG AGT TTG GGA GAT TTT GGA GAT ATA ATT ATG GGA 239AAG GAT ATA ACA TGG AGT TTG GGA GAT TTT GGA GAT ATA ATT ATG GGA 239
Lys Asp Ile Thr Trp Ser Leu Gly Asp Phe Gly Asp Ile Ile Met GlyLys Asp Ile Thr Trp Ser Leu Gly Asp Phe Gly Asp Ile Ile Met Gly
295 300 305295 300 305
ACG GAT ATG GAA GGC ATC GGA TAT TCC GAA GTA GTG GAA AAT AAT TTG 287ACG GAT ATG GAA GGC ATC GGA TAT TCC GAA GTA GTG GAA AAT AAT TTG 287
Thr Asp Met Glu Gly Ile Gly Tyr Ser Glu Val Val Glu Asn Asn LeuThr Asp Met Glu Gly Ile Gly Tyr Ser Glu Val Val Glu Asn Asn Leu
310 315 320310 315 320
CGC AGC ATC TTT GGA ACT GGT GAA AAG GCC CAA CAG CAT CGT AAA CAG 335CGC AGC ATC TTT GGA ACT GGT GAA AAG GCC CAA CAG CAT CGT AAA CAG 335
Arg Ser Ile Phe Gly Thr Gly Glu Lys Ala Gln Gln His Arg Lys GlnArg Ser Ile Phe Gly Thr Gly Glu Lys Ala Gln Gln His Arg Lys Gln
325 330 335325 330 335
TGG TGG AAT GAA TCT AAA GCA CAA ATT TGG ACA GCA ATG ATG TAC TCA 383TGG TGG AAT GAA TCT AAA GCA CAA ATT TGG ACA GCA ATG ATG TAC TCA 383
Trp Trp Asn Glu Ser Lys Ala Gln Ile Trp Thr Ala Met Met Tyr SerTrp Trp Asn Glu Ser Lys Ala Gln Ile Trp Thr Ala Met Met Tyr Ser
340 345 350340 345 350
GTT AAA AAA AGA TTA AAG GGG AAA TTT ATA TGG ATT TGT AAA ATA AAT 431GTT AAA AAA AGA TTA AAG GGG AAA TTT ATA TGG ATT TGT AAA ATA AAT 431
Val Lys Lys Arg Leu Lys Gly Lys Phe Ile Trp Ile Cys Lys Ile AsnVal Lys Lys Arg Leu Lys Gly Lys Phe Ile Trp Ile Cys Lys Ile Asn
355 360 365 370355 360 365 370
GTT GCG GTA AAT ATA GAA CCG CAG ATA TAT AGA CGG ATT CGA GAA TGG 479GTT GCG GTA AAT ATA GAA CCG CAG ATA TAT AGA CGG ATT CGA GAA TGG 479
Val Ala Val Asn Ile Glu Pro Gln Ile Tyr Arg Arg Ile Arg Glu TrpVal Ala Val Asn Ile Glu Pro Gln Ile Tyr Arg Arg Ile Arg Glu Trp
375 380 385375 380 385
GGA AGG GAT TAC GTG TCA GAA TTG CCC ACA GAA GTG CCA AAA CTG AAA 527GGA AGG GAT TAC GTG TCA GAA TTG CCC ACA GAA GTG CCA AAA CTG AAA 527
Gly Arg Asp Tyr Val Ser Glu Leu Pro Thr Glu Val Pro Lys Leu LysGly Arg Asp Tyr Val Ser Glu Leu Pro Thr Glu Val Pro Lys Leu Lys
390 395 400390 395 400
GAA AAA TGT GAT GGA AAA ATC AAT TAT ACT GAT AAA AAA GTA TGT AAG 575GAA AAA TGT GAT GGA AAA ATC AAT TAT ACT GAT AAA AAA GTA TGT AAG 575
Glu Lys Cys Asp Gly Lys Ile Asn Tyr Thr Asp Lys Lys Val Cys LysGlu Lys Cys Asp Gly Lys Ile Asn Tyr Thr Asp Lys Lys Val Cys Lys
405 410 415405 410 415
GTA CCA CCA TGT CAA AAT GCG TGT AAA TCA TAT GAT CAA TGG ATA ACC 623GTA CCA CCA TGT CAA AAT GCG TGT AAA TCA TAT GAT CAA TGG ATA ACC 623
Val Pro Pro Cys Gln Asn Ala Cys Lys Ser Tyr Asp Gln Trp Ile ThrVal Pro Pro Cys Gln Asn Ala Cys Lys Ser Tyr Asp Gln Trp Ile Thr
420 425 430420 425 430
AGA AAA AAA AAT CAA TGG GAT GTT CTG TCA AAT AAA TTC AAA AGT GTA 671AGA AAA AAA AAT CAA TGG GAT GTT CTG TCA AAT AAA TTC AAA AGT GTA 671
Arg Lys Lys Asn Gln Trp Asp Val Leu Ser Asn Lys Phe Lys Ser ValArg Lys Lys Asn Gln Trp Asp Val Leu Ser Asn Lys Phe Lys Ser Val
435 440 445 450435 440 445 450
AAA AAC GCA GAA AAG GTT CAG ACG GCA GGT ATC GTA ACT CCT TAT GAT 719AAA AAC GCA GAA AAG GTT CAG ACG GCA GGT ATC GTA ACT CCT TAT GAT 719
Lys Asn Ala Glu Lys Val Gln Thr Ala Gly Ile Val Thr Pro Tyr AspLys Asn Ala Glu Lys Val Gln Thr Ala Gly Ile Val Thr Pro Tyr Asp
455 460 465455 460 465
ATA CTA AAA CAG GAG TTA GA 739ATA CTA AAA CAG GAG TTA GA 739
Ile Leu Lys Gln Glu LeuIle Leu Lys Gln Glu Leu
470470
(2) 서열번호6에 대한 정보:(2) Information about SEQ ID NO:
(i) 서열의 특징:(i) sequence characteristics:
(A) 길이: 245 amino acids(A) Length: 245 amino acids
(B) 타입: 아미노산(B) type: amino acid
(D) 토폴로지 : 선형(D) topology: linear
(ii) 분자의 타입: 단백질(ii) Type of molecule: protein
(xi) 서열의 기재방법: SEQ ID NO: 6:(xi) Sequence description: SEQ ID NO: 6:
Ile Pro Asp Arg Arg Tyr Gln Leu Cys Met Lys Glu Leu Thr Asn LeuIle Pro Asp Arg Arg Tyr Gln Leu Cys Met Lys Glu Leu Thr Asn Leu
1 5 10 151 5 10 15
Val Asn Asn Thr Asp Thr Asn Phe His Arg Asp Ile Thr Phe Arg LysVal Asn Asn Thr Asp Thr Asn Phe His Arg Asp Ile Thr Phe Arg Lys
20 25 3020 25 30
Leu Tyr Leu Lys Arg Lys Leu Ile Tyr Asp Ala Ala Val Glu Gly AspLeu Tyr Leu Lys Arg Lys Leu Ile Tyr Asp Ala Ala Val Glu Gly Asp
35 40 4535 40 45
Leu Leu Leu Lys Leu Asn Asn Tyr Arg Tyr Asn Lys Asp Phe Cys LysLeu Leu Leu Lys Leu Asn Asn Tyr Arg Tyr Asn Lys Asp Phe Cys Lys
50 55 6050 55 60
Asp Ile Thr Trp Ser Leu Gly Asp Phe Gly Asp Ile Ile Met Gly ThrAsp Ile Thr Trp Ser Leu Gly Asp Phe Gly Asp Ile Ile Met Gly Thr
65 70 75 8065 70 75 80
Asp Met Glu Gly Ile Gly Tyr Ser Glu Val Val Glu Asn Asn Leu ArgAsp Met Glu Gly Ile Gly Tyr Ser Glu Val Val Glu Asn Asn Leu Arg
85 90 9585 90 95
Ser Ile Phe Gly Thr Gly Glu Lys Ala Gln Gln His Arg Lys Gln TrpSer Ile Phe Gly Thr Gly Glu Lys Ala Gln Gln His Arg Lys Gln Trp
100 105 110100 105 110
Trp Asn Glu Ser Lys Ala Gln Ile Trp Thr Ala Met Met Tyr Ser ValTrp Asn Glu Ser Lys Ala Gln Ile Trp Thr Ala Met Met Tyr Ser Val
115 120 125115 120 125
Lys Lys Arg Leu Lys Gly Lys Phe Ile Trp Ile Cys Lys Ile Asn ValLys Lys Arg Leu Lys Gly Lys Phe Ile Trp Ile Cys Lys Ile Asn Val
130 135 140130 135 140
Ala Val Asn Ile Glu Pro Gln Ile Tyr Arg Arg Ile Arg Glu Trp GlyAla Val Asn Ile Glu Pro Gln Ile Tyr Arg Arg Ile Arg Glu Trp Gly
145 150 155 160145 150 155 160
Arg Asp Tyr Val Ser Glu Leu Pro Thr Glu Val Pro Lys Leu Lys GluArg Asp Tyr Val Ser Glu Leu Pro Thr Glu Val Pro Lys Leu Lys Glu
165 170 175165 170 175
Lys Cys Asp Gly Lys Ile Asn Tyr Thr Asp Lys Lys Val Cys Lys ValLys Cys Asp Gly Lys Ile Asn Tyr Thr Asp Lys Lys Val Cys Lys Val
180 185 190180 185 190
Pro Pro Cys Gln Asn Ala Cys Lys Ser Tyr Asp Gln Trp Ile Thr ArgPro Pro Cys Gln Asn Ala Cys Lys Ser Tyr Asp Gln Trp Ile Thr Arg
195 200 205195 200 205
Lys Lys Asn Gln Trp Asp Val Leu Ser Asn Lys Phe Lys Ser Val LysLys Lys Asn Gln Trp Asp Val Leu Ser Asn Lys Phe Lys Ser Val Lys
210 215 220210 215 220
Asn Ala Glu Lys Val Gln Thr Ala Gly Ile Val Thr Pro Tyr Asp IleAsn Ala Glu Lys Val Gln Thr Ala Gly Ile Val Thr Pro Tyr Asp Ile
225 230 235 240225 230 235 240
Leu Lys Gln Glu LeuLeu Lys Gln Glu Leu
245245
(2) 서열번호7에 대한 정보:(2) Information about SEQ ID NO:
(i) 서열의 특징:(i) sequence characteristics:
(A) 길이: 28 base pairs(A) Length: 28 base pairs
(B) 타입: 핵산(B) Type: nucleic acid
(C) 쇄의 수 : 1본쇄(C) Number of chains: 1 chain
(D) 토폴로지 : 선형(D) topology: linear
(ii) 분자의 타입: DNA(ii) Type of molecule: DNA
(vi) 기원:(vi) origin:
(A) 생물명: 합성 유전자(A) biological name: synthetic gene
(xi) 서열의 기재방법: SEQ ID NO: 7:(xi) Sequence description: SEQ ID NO: 7:
GTCGGAATTC ATGAAGAACT TCATTCTC 28GTCGGAATTC ATGAAGAACT TCATTCTC 28
(2) 서열번호8에 대한 정보:(2) Information about SEQ ID NO:
(i) 서열의 특징:(i) sequence characteristics:
(A) 길이: 23 base pairs(A) Length: 23 base pairs
(B) 타입: 핵산(B) Type: nucleic acid
(C) 쇄의 수 : 1본쇄(C) Number of chains: 1 chain
(D) 토폴로지 : 선형(D) topology: linear
(ii) 분자의 타입: DNA(ii) Type of molecule: DNA
(vi) 기원:(vi) origin:
(A) 생물명: 합성 유전자(A) biological name: synthetic gene
(xi) 서열의 기재방법: SEQ ID NO: 8:(xi) Sequence description: SEQ ID NO: 8:
GAGGACGCCG AAAATAATGG ATG 23GAGGACGCCG AAAATAATGG ATG 23
(2) 서열번호9에 대한 정보:(2) Information about SEQ ID NO:
(i) 서열의 특징:(i) sequence characteristics:
(A) 길이: 22 base pairs(A) Length: 22 base pairs
(B) 타입: 핵산(B) Type: nucleic acid
(C) 쇄의 수 : 1본쇄(C) Number of chains: 1 chain
(D) 토폴로지 : 선형(D) topology: linear
(ii) 분자의 타입: DNA(ii) Type of molecule: DNA
(vi) 기원:(vi) origin:
(A) 생물명: 합성 유전자(A) biological name: synthetic gene
(xi) 서열의 기재방법: SEQ ID NO: 9:(xi) Sequence description: SEQ ID NO: 9:
GAGCCCTACT ACTTGATGGT CC 22GAGCCCTACT ACTTGATGGT CC 22
(2) 서열번호10에 대한 정보:(2) Information about SEQ ID NO: 10:
(i) 서열의 특징:(i) sequence characteristics:
(A) 길이: 20 base pairs(A) Length: 20 base pairs
(B) 타입: 핵산(B) Type: nucleic acid
(C) 쇄의 수 : 1본쇄(C) Number of chains: 1 chain
(D) 토폴로지 : 선형(D) topology: linear
(ii) 분자의 타입: DNA(ii) Type of molecule: DNA
(vi) 기원:(vi) origin:
(A) 생물명: 합성 유전자(A) biological name: synthetic gene
(xi) 서열의 기재방법: SEQ ID NO: 10:(xi) Method of describing sequence: SEQ ID NO: 10:
CCTTCTGGTA CAGCTCAATG 20CCTTCTGGTA CAGCTCAATG 20
(2) 서열번호11에 대한 정보:(2) Information about SEQ ID NO:
(i) 서열의 특징:(i) sequence characteristics:
(A) 길이: 22 base pairs(A) Length: 22 base pairs
(B) 타입: 핵산(B) Type: nucleic acid
(C) 쇄의 수 : 1본쇄(C) Number of chains: 1 chain
(D) 토폴로지 : 선형(D) topology: linear
(ii) 분자의 타입: DNA(ii) Type of molecule: DNA
(vi) 기원:(vi) origin:
(A) 생물명: 합성 유전자(A) biological name: synthetic gene
(xi) 서열의 기재방법 : SEQ ID NO 11:(xi) Sequence description: SEQ ID NO 11:
TGGGACTGTA ACACTAAGAA GG 22TGGGACTGTA ACACTAAGAA GG 22
(2) 서열번호12에 대한 정보:(2) Information about SEQ ID NO: 12:
(i) 서열의 특징:(i) sequence characteristics:
(A) 길이: 22 base pairs(A) Length: 22 base pairs
(B) 타입: 핵산(B) Type: nucleic acid
(C) 쇄의 수 : 1본쇄(C) Number of chains: 1 chain
(D) 토폴로지 : 선형(D) topology: linear
(ii) 분자의 타입: DNA(ii) Type of molecule: DNA
(vi) 기원:(vi) origin:
(A) 생물명: 합성 유전자(A) biological name: synthetic gene
(xi) 서열의 기재방법: SEQ ID NO: 12:(xi) a method for describing a sequence: SEQ ID NO: 12:
TTCATTCTCA AAAGCCACCT CG 22TTCATTCTCA AAAGCCACCT CG 22
(2) 서열번호13에 대한 정보:(2) Information about SEQ ID NO:
(i) 서열의 특징:(i) sequence characteristics:
(A) 길이: 9 amino acids(A) Length: 9 amino acids
(B) 타입: 아미노산(B) type: amino acid
(D) 토폴로지 : 선형(D) topology: linear
(ii) 분자의 타입: 펩티드(ii) Type of molecule: peptide
(xi) 서열의 기재방법: SEQ ID NO: 13:(xi) Sequence description: SEQ ID NO: 13:
Ala Gly Asn Gly Ala Gly Gly Gln Pro 9Ala Gly Asn Gly Ala Gly Gly Gln Pro 9
(2) 서열번호14에 대한 정보:(2) Information about SEQ ID NO: 14
(i) 서열의 특징:(i) sequence characteristics:
(A) 길이: 9 amino acids(A) Length: 9 amino acids
(B) 타입: 아미노산(B) type: amino acid
(D) 토폴로지 : 선형(D) topology: linear
(ii) 분자의 타입: 펩티드(ii) Type of molecule: peptide
(xi) 서열의 기재방법: SEQ ID NO: 14:(xi) Sequence description: SEQ ID NO: 14:
Ala Gly Asn Gly Ala Gly Gly Gln Ala 9Ala Gly Asn Gly Ala Gly Gly Gln Ala 9
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019980039110A KR20000020495A (en) | 1998-09-21 | 1998-09-21 | Detection method of malaria |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019980039110A KR20000020495A (en) | 1998-09-21 | 1998-09-21 | Detection method of malaria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20000020495A true KR20000020495A (en) | 2000-04-15 |
Family
ID=19551400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019980039110A Abandoned KR20000020495A (en) | 1998-09-21 | 1998-09-21 | Detection method of malaria |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20000020495A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100373918B1 (en) * | 2000-02-17 | 2003-02-26 | 주식회사 엘지생명과학 | Enzyme immuno assay for malaria and reagent used therefor |
-
1998
- 1998-09-21 KR KR1019980039110A patent/KR20000020495A/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100373918B1 (en) * | 2000-02-17 | 2003-02-26 | 주식회사 엘지생명과학 | Enzyme immuno assay for malaria and reagent used therefor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Snounou et al. | Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections | |
| Kirchhoff et al. | Comparison of PCR and microscopic methods for detecting Trypanosoma cruzi | |
| De Monbrison et al. | Simultaneous identification of the four human Plasmodium species and quantification of Plasmodium DNA load in human blood by real-time polymerase chain reaction | |
| Ryan et al. | Evidence for transmission of Plasmodium vivax among a duffy antigen negative population in Western Kenya | |
| Bruce et al. | Polymorphism at the merozoite surface protein-3alpha locus of Plasmodium vivax: global and local diversity. | |
| Bharti et al. | Experimental infection of the neotropical malaria vector Anopheles darlingi by human patient-derived Plasmodium vivax in the Peruvian Amazon | |
| Kimura et al. | Species-specific PCR detection of malaria parasites by microtiter plate hybridization: clinical study with malaria patients | |
| Silva et al. | detection of Leishmania DNA by polymerase chain reaction on blood samples from dogs with visceral leishmaniasis. | |
| Toma et al. | A field study on malaria prevalence in southeastern Laos by polymerase chain reaction assay | |
| Alloueche et al. | High-throughput sequence typing of T-cell epitope polymorphisms in Plasmodium falciparum circumsporozoite protein | |
| Nyeko et al. | Characterization of trypanosome isolates from cattle in Uganda using species-specific DNA probes reveals predominance of mixed infections | |
| Arai et al. | DNA diagnosis of ovale malaria and malariae malaria using microtiter plate-hybridization | |
| KR20000020495A (en) | Detection method of malaria | |
| KR20000020497A (en) | Detection method of malaria | |
| KR20000020496A (en) | Detection method of malaria | |
| Holmberg et al. | Diagnosis of Plasmodium falciparum infection by spot hybridization assay: specificity, sensitivity, and field applicability | |
| KR101847422B1 (en) | Composition for diagnosing malaria infection using LAMP and uses thereof | |
| Puente et al. | The use of PCR in the diagnosis of hyper-reactive malarial splenomegaly (HMS) | |
| Cole-Tobian et al. | Dynamics of asymptomatic Plasmodium vivax infections and Duffy binding protein polymorphisms in relation to parasitemia levels in Papua New Guinean children | |
| Al-Hosary et al. | New approach to use blood smears for diagnosis of bovine theileriosis | |
| Win et al. | Detection of Plasmodium ovale by the ICT malaria Pf/Pv immunochromatographic test | |
| Tanabe et al. | A PCR method for molecular epidemiology of Plasmodium falciparum msp-1 | |
| JP3828022B2 (en) | Plasmodium vivax and its diagnosis | |
| Touria et al. | Epidemiology of infantile visceral leishmaniasis in Western Algerian and the convenience of serum for the disease diagnosis by PCR and immunochromatography | |
| Oyeniran et al. | The Incidence of Asymptomatic and Symptomatic Malaria Infection in HIV Positive and Negative Individuals in Osun State, Nigeria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19980921 |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19980921 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20000731 Patent event code: PE09021S01D |
|
| PC1902 | Submission of document of abandonment before decision of registration | ||
| SUBM | Surrender of laid-open application requested |